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ABSTRACT
The U.S. is often characterized as a leader in innovation—a home
of Nobel Prize‐winning scientists, innovators, and abundant research
funding. Yet, in the area of assisted reproduction combined with
genetic modification or substitution, what I call “reproductive genetic
innovation,” that characterization begins to wane. This Article focuses
on the regulation of mitochondrial transfer, a subset of reproductive
genetic innovation. While human clinical trials related to
mitochondrial transfer go forward in the U.K., the clinical use of the
technique remains illegal in the U.S. due to a system of subterranean
regulation by the U.S. Food and Drug Administration and a now‐
recurring federal budget rider.
In the U.K., the government structured and carried out a public
consultation as part of the legalization of mitochondrial transfer.
Recently, Australia announced a plan to consider the potential
legalization of mitochondrial transfer. In August 2021, the Australian
federal government completed a public‐facing step in implementing a
gradual approach to considering the legalization of mitochondrial
transfer, and in March 2022, Maeve’s Bill passed in the Australian
Parliament.
This Article draws on the experiences of two common‐law
countries, the United Kingdom and Australia, to identify potential
avenues for a gradual approach to legalizing mitochondrial transfer in
the United States. Progress on mitochondrial transfer could start a
broader American discourse that could facilitate access to
mitochondrial transfer and the other techniques in the area of
reproductive genetic innovation.
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INTRODUCTION
The United States is a leader in science and innovation. Recent
data shows that the United States spends more on research and
development than any other country in the world.1 Yet, the United
States’ research spending lead has narrowed over the years.2 Currently
while the U.S. is ranked first in research and development spending,
China is second, the United Kingdom is seventh , and Australia is
thirteenth.3
The United States has been a leader in other areas of technological
and medical innovation, but it lags the U.K, not only in insurance
coverage of fertility treatments but also in terms of the pace of
innovation.4 A few years ago, mitochondrial transfer—a technique that
combines in vitro fertilization (IVF) with genetic substitution—was the
subject of significant media attention, especially as the United
Kingdom debated and ultimately legalized the use of the technique.5
As will be detailed in Part I, mitochondrial transfer could not only
improve fertility outcomes but also prevent the transmission of
harmful genetic diseases like Leigh Syndrome that have severe

1 JOHN F. SARGENT JR., CONG. RSCH. SERV., R44283, GLOBAL RESCH. & DEV. EXPENDITURES: FACT

SHEET 2 (2020), https://crsreports.congress.gov/product/pdf/R/R44283/13; Mark Boroush,
Research & Development: U.S. Trends and International Comparisons, NAT’L SCI. BD. (Jan. 15,
2020), https://ncses.nsf.gov/pubs/nsb20203/cross‐national‐comparisons‐of‐r‐d‐performance.
2

SARGENT JR., supra note 1, at 1.

3

Id. at 2.

4

For more on insurance coverage for ART, see e.g., June Carbone & Naomi Cahn, Embryo
Fundamentalism, 18 WM. & MARY BILL RTS. J. 1015, 1031–32 (2010); BRYCE H.P. MENDEZ, CONG.
RSCH.
SERV.,
IF11504,
INFERTILITY
IN
THE
MILITARY
(2021),
https://crsreports.congress.gov/product/pdf/IF/IF11504.

5

Mitochondrial transfer is also referred to as “mitochondrial replacement therapy” or
“mitochondrial donation therapy.” Brittany Shoot, 3‐Parent IVF: Why Isn’t It Available in the
United
States?,
THE
GUARDIAN
(Feb.
27,
2015,
8:22
PM),
https://www.theguardian.com/sustainable‐business/2015/feb/27/3‐parent‐ivf‐us‐
mitochondria‐dna‐babies [https://perma.cc/RHM9‐96VA]; Julian Savulescu, Mitochondrial
Disease Kills 150 Children a Year. A Micro‐Transplant Can Cure It., THE GUARDIAN (Feb. 2, 2015),
https://www.theguardian.com/science/2015/feb/02/mitochondrial‐transfer‐micro‐transplant‐
parliamentary‐debate; Rafqa Touma, Mitochondrial Donation: How an IVF Procedure Could Help
Australian Families ‘Break the Genetic Chain’, THE GUARDIAN (June 5, 2021, 4:00 PM),
https://www.theguardian.com/australia‐news/2021/jun/06/mitochondrial‐donation‐how‐an‐
ivf‐procedure‐could‐help‐australian‐families‐break‐the‐genetic‐chain.
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negative impacts on organs such as the brain, heart, and kidneys.6
Mitochondrial transfer continues to inhabit the scientific and popular
spheres, as babies continue to be born as a result of the technique in
Ukraine, Greece, and Mexico.7 This Article focuses on the experiences
of the United Kingdom and Australia in the legalization of
mitochondrial transfer.8 In doing so, the Article contributes to the
assisted reproductive technology (“ART”), innovation, administrative
law, and drug law literatures.9
Mitochondrial transfer, a technique that combines IVF with
genetic substitution, has been legalized for human clinical research
and use in the United Kingdom while the technique remains
effectively banned in the United States by both FDA and

6

Leigh
Syndrome,
GENETICS
HOME
REFERENCE
(Aug.
17,
2020),
https://ghr.nlm.nih.gov/condition/leigh‐syndrome#genes; see infra Part I.(A); see also Emily
Mullin, The Fertility Doctor Trying to Commercialize Three‐Parent Babies, MIT TECH. REV. (Jun.
13, 2017), https://www.technologyreview.com/2017/06/13/151273/the‐fertility‐doctor‐trying‐
to‐commercialize‐three‐parent‐babies/; U.S. FOOD & DRUG ADMIN., TRANSCRIPT OF CENTER
FOR BIOLOGICS EVALUATION AND RESEARCH BIOLOGICAL RESPONSE MODIFIERS ADVISORY
COMMITTEE OPEN SESSION MEETING #32, 42, 77, 134, 226 (2002) [hereinafter MEETING #32
TRANSCRIPT]; Jason Barritt et al., Epigenetic and Experimental Modifications in Early Mammalian
Development: Part II Cytoplasmic Transfer in Assisted Reproduction, 7 HUM. REPROD. UPDATE 428,
433–34 (2001); Alice Park, Experts Are Calling for a Ban on Gene Editing of Human Embryos. Here’s
Why They’re Worried, TIME (Mar. 13, 2019, 2:22 PM), https://time.com/5550654/crispr‐gene‐
editing‐human‐embryos‐ban/; Henry T. Greely, CRISPR’d Babies: Human Germline Genome
Editing in the ‘He Jiankui Affair’, 6 J. L. & BIOSCIENCES. 111, 114 (2019) (“not all human germline
genome editing must be embryo editing. One could take eggs and sperm from people and, ex
vivo, edit them before using these edited gametes to create an embryo, rather than edit the
embryo itself.”).

7

See, e.g., Tetsuya Ishii & Yuri Hibino, Mitochondrial Manipulation in Fertility Clinics: Regulation
and Responsibility, 5 REPROD. BIOMEDICINE & SOC’Y ONLINE 93, 93 (2018) (“It was found that
regulation of the clinical use of [mitochondrial manipulation techniques] could be broken
down into three categories: (i) largely prohibited (USA and China), (ii) not regulated
(Northern Cyprus and Ukraine), and (iii) insufficiently regulated (the remaining 12 countries,
including Mexico).”); see also Emily Mullin, Patient Advocates and Scientists Launch Push to Lift
Ban
on
‘Three‐Parent
IVF’,
STAT
NEWS
(Apr.
16,
2019),
https://www.statnews.com/2019/04/16/mitochondrial‐replacement‐three‐parent‐ivf‐ban/;
Bianca Nogrady, Australia Moves a Step Closer to ‘Three‐Person IVF’, NATURE (June 29, 2018),
https://www.nature.com/articles/d41586‐018‐05451‐z; Erik Robinson, Long‐Term Study of
Mitochondrial Replacement Therapy in Monkeys Finds No Adverse Health Effects, OHSU: NEWS
(Dec.
8,
2020),
https://news.ohsu.edu/2020/12/08/long‐term‐study‐of‐mitochondrial‐
replacement‐therapy‐in‐monkeys‐finds‐no‐adverse‐health‐effects.

8

Shoot, supra note 5; Savulescu,supra note 5; Touma, supra note 5.

9

See discussion infra in Parts I.B and III.C.
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Congressional action.10 Regulatory progress has essentially stalled in
the United States, and there is little hope for imminent change. On the
topic of the progress (or lack thereof) of mitochondrial transfer in the
U.S., Dr. Eli Adashi has noted “It was really an American
idea…[w]hich makes it all the more unfortunate that it has been
restricted here.”11
While the U.S. regulatory system remains at a standstill with
minimal inquiry into mitochondrial transfer, Australia has been
engaged in a public inquiry since 2018. In 2021, after hearing the story
of a 5‐year‐old girl named Maeve Hood who was diagnosed with
Leigh Syndrome, a debilitating form of mitochondrial disease, a
Victorian Parliament member introduced “Mitochondrial Donation
Law Reform (Maeve’s Law) Bill 2021” in the Australian Senate,
hereinafter referred to as “Maeve’s bill.”12 Maeve’s bill is based on the
U.K.’s legislation legalizing mitochondrial transfer.13 The Australian
Health Minister, Greg Hunt, supported the law, as did the

10

See Lyria Bennett Moses, Understanding Legal Responses to Technological Change: The Example of
In Vitro Fertilization, 6 MINN. J.L. SCI. & TECH. 505, 506‐07 (2005); Emily Mullin, Pregnancy
Reported in the First Known Trial of “Three‐Person IVF” for Infertility, STAT NEWS (Jan. 24, 2019)
https://www.statnews.com/2019/01/24/first‐trial‐of‐three‐person‐ivf‐for‐infertility/;
Mitochondrial Donation Treatment, HUM. FERTILISATION & EMBRYOLOGY AUTH.,
https://www.hfea.gov.uk/treatments/embryo‐testing‐and‐treatments‐for‐
disease/mitochondrial‐donation‐treatment/ [hereinafter HUM. FERTILISATION & EMBRYOLOGY
AUTH.]; Louise Brown: World’s First IVF Baby’s Family Archive Unveiled, BBC NEWS: BRISTOL
(July 25, 2018), https://www.bbc.com/news/uk‐england‐bristol‐44940929; Mitochondrial
Donation Law Reform (Maeve’s Law) Bill 2021, Public Hearing Transcript, THE SENATE CMTY.
AFFS.
LEGIS.
COMM.
(Aug.
6,
2021),
https://www.aph.gov.au/Parliamentary_Business/Committees/Senate/Community_Affairs/
MitochondrialLawReform/Public_Hearings [hereinafter Public Hearing Transcript] (noting
that there may not be confirmation from the UK. Government when or if a pregnancy is
achieved because of mitochondrial transfer).

11

Radhika Viswanathan, 3 Biological Parents, 1 Child, and an International Controversy, VOX (Jul.
28, 2018, 10:00 AM), https://www.vox.com/2018/7/24/17596354/mitochondrial‐replacement‐
therapy‐three‐parent‐baby‐controversy.

12

Emily McPherson, How a Five‐Year‐Old Girl Inspired Proposed DNA Donation Laws, 9 NEWS
(Mar. 24, 2021, 1:26 PM), https://www.9news.com.au/national/mitochondria‐disease‐
explainer‐how‐a‐five‐year‐old‐girl‐inspired‐proposed‐new‐dna‐donation‐laws/03d5dd35‐
2c65‐4157‐841b‐56b486bd0013; see Making a Law in the Australian Parliament, PARLIAMENTARY
EDUC. OFF., https://peo.gov.au/understand‐our‐parliament/how‐parliament‐works/bills‐
and‐laws/making‐a‐law‐in‐the‐australian‐parliament/ (explaining that “[a] bill can only
become a law if it is passed by a majority vote in the Senate and the House of
Representatives.”).

13

McPherson, supra note 12.
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International Society for Stem Cell Research (ISSCR).14 In December
2021, Maeve’s bill passed in the Australian House of Representatives
and in March 2022, it passed in the Australian Senate.15 Maeve’s law
commenced on October 1, 2022.16
In previous articles, I have argued for the legalization of
mitochondrial transfer in the United States.17 This Article continues
that argument and focuses on ways to use public deliberation in
furtherance of that legalization. As such, the Article identifies those
tools of deliberative democracy that have been successful in other
countries, as they may prove useful in response to American (and
foreign) scientists’ continued calls for a public discourse related to
genetic modification.18 If societal discourse will impact regulatory
decisions such that the lack of a societal discourse or widespread
acceptance will continue to lead to an effective ban on reproductive
genetic innovation, then society will need to decide whether to have
that discussion and how that discussion would even be structured if it
did occur.19 The U.K. and Australian experiences could also be part of
14

Id.; Letter from Melissa H. Little, President, ISSCR, to Senators Wendy Askew & Rachel
Siewert (July 16, 2021) (on file with Hous. J. Health L. & Pol’y).

15

Sarah Martin, Controversial Mitochondrial Donation Legislation Passed After Conscience Vote, THE
GUARDIAN
(Dec.
1,
2021),
https://www.theguardian.com/australia‐
news/2021/dec/01/controversial‐mitochondrial‐donation‐legalised‐after‐conscience‐vote;
Kimberly Caines, Maeve’s Law: Mitochondrial Disease Bill Pushed to Next Year Could Delay Family
Planning, THE WEST AUSTRALIAN, https://thewest.com.au/politics/federal‐politics/maeves‐
law‐mitochondrial‐disease‐bill‐pushed‐to‐next‐year‐could‐delay‐family‐planning‐c‐
4803222; Mitochondrial Donation Law Reform (Maeve’s Law) Bill 2021 (Cth) (Austl.),
https://www.aph.gov.au/Parliamentary_Business/Bills_LEGislation/Bills_Search_Results/Re
sult?bId=r6697 [hereinafter Mitochondrial Donation Law Reform (Maeve’s Law) Bill 2021].

16

Mitochondrial Donation, AUSTL. GOV’T DEP’T HEALTH & AGED CARE (Oct. 3, 2022),
https://www.health.gov.au/initiatives‐and‐programs/mitochondrial‐donation (noting that
Maeve’s law was assented to on April 1, 2022).

17

Myrisha S. Lewis, How Subterranean Regulation Hinders Innovation in Assisted Reproductive
Technology, 39 CARDOZO L. REV. 1239 (2018); Myrisha S. Lewis, How Analogizing Socio‐Legal
Responses to Organ Transplantation Can Further the Legalization of Reproductive Genetic
Innovation, 74 SMU L. REV. 665 (2021).

18

For more on the benefits of deliberative democracy, see generally Nicole Curato et al., Twelve
Key Findings in Deliberative Democracy Research, 146 DÆDALUS 28 (2017); Melissa De Witte,
Could Deliberative Democracy Depolarize America? Stanford Scholars Think So, STAN. NEWS (Feb.
4, 2021), https://news.stanford.edu/2021/02/04/deliberative‐democracy‐depolarize‐america/.

19

While there have been several International Summits on Gene Editing, convened by various
bodies, including the National Academies of Sciences, there has been no equivalent
“national” summit, convened by any regulatory agency. See Part I B‐C and II.A‐B (discussing
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a piecemeal approach to the larger issue of reproductive genetic
innovation in the United States and other countries.
Part I of the Article provides brief scientific and bioethical
background on mitochondrial transfer. Part II provides regulatory
background on assisted reproductive technology and mitochondrial
transfer in the United States, United Kingdom, and Australia. Part III
identifies and explains which of the regulatory and deliberative
mechanisms used in the United Kingdom’s and Australia’s
legalizations of mitochondrial transfer could be adapted for use in the
United States. The Article then concludes.

I. MITOCHONDRIAL TRANSFER
Assisted reproductive technology is becoming increasingly
prevalent in the U.S. and abroad and enjoys widespread support in the
United States.20 Assisted reproduction, including IVF, is legal and
widely available in the United States.21 There are also forms of assisted
reproduction that involve deliberate genetic changes, what I call
“reproductive
genetic
innovation”:
cytoplasmic
transfer,
mitochondrial transfer, and germline genome editing. Cytoplasmic
transfer was a technique used in the late 1990s to improve fertility
outcomes, and germline (heritable) gene editing in human embryos
could prevent the inheritance of disease‐causing mutations.22
Reproductive genetic innovation techniques are largely classified as
“experimental” by the regulatory system and many observers

the regulation of reproductive genetic innovation).
20

Carbone & Cahn, supra note 4, at 1031–32 (2010) (noting that “support for IVF is widespread—
three‐quarters of the American public approves of IVF—and the fifteen states that have
mandated some form of insurance for fertility services seem to be a random assortment that
include Arkansas, California, Connecticut, Hawaii, Illinois, Louisiana, Maryland,
Massachusetts, Montana, New Jersey, New York, Ohio, Rhode Island, Texas, and West
Virginia.” (citations omitted)).

21

See, e.g., CTRS. FOR DISEASE CONTROL & PREVENTION, ASSISTED REPROD. TECH. SURVEILLANCE—
U.S., 2017, MORBIDITY & MORTALITY WEEKLY REP. ( 2020).

22

The U.S. Food and Drug Administration, medical establishment, and much of the public view
these techniques as “experimental.” See MEETING #32 TRANSCRIPT, supra note 6, at 46, 80;
Barritt et al., supra note 6, at 433‐34.; Park, supra note 6.
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although some of the techniques have been used by U.S.‐based
physicians and continue to be researched and used abroad.23
While germline genetic modification has been the subject of x
“bombshell” news such as Dr. He Jiankui’s use of germline gene
editing in embryos that led to the birth of three children, mitochondrial
transfer does not receive as much media attention these days but
remains significant.24 This Article will focus on the legalization of
mitochondrial transfer although the implications of the Article’s
arguments related to mitochondrial transfer could be applied to
reproductive genetic innovation, including cytoplasmic transfer and
germline gene editing, more broadly.25 Section A of this Part provides
scientific background on mitochondrial transfer. Section B of this Part
provides a brief overview of the ethical controversy that accompanies
mitochondrial transfer.

A. Scientific Background
Mitochondrial transfer (also referred to as “mitochondrial
donation therapy” or “mitochondrial replacement therapy”) is a type
of assisted reproductive technology involving the use of in vitro
fertilization and the substitution of genetic material.26 Mitochondrial
transfer targets the mitochondria of a cell, which are organelles found
in the cytoplasm of the cell.27 Mitochondria have their own DNA
which is generally believed to be inherited solely from the mother.28

23

See discussion supra in the Introduction of countries where mitochondrial transfer and
techniques involving reproductive genetic innovation, have been provided to parents.

24

Greely, supra note 6, at 115, 140; R. Alta Charo, Rogues and Regulation of Germline Editing, 380
N. ENGL. J. MED. 976 (2019).

25

See GEOFF WATTS ET AL., NUFFIELD COUNCIL ON BIOETHICS, NOVEL TECHNIQUES FOR THE
PREVENTION OF MITOCHONDRIAL DNA DISORDERS: AN ETHICAL REVIEW 34–36 (Nuffield
Council
on
Bioethics,
2012),
https://www.nuffieldbioethics.org/assets/pdfs/Novel_techniques_for_the_prevention_of_mi
tochondrial_DNA_disorders.pdf; Sharon Begley, Gene‐Editing Discovery Could Point the Way
Toward a ‘Holy Grail’: Cures for Mitochondrial Diseases, STAT NEWS (July 8, 2020),
https://www.statnews.com/2020/07/08/unexpected‐email‐leads‐to‐discovery‐of‐first‐
genome‐editor‐for‐mitochondria/.

26

See, e.g., WATTS ET AL., supra note 25, at 36, 38.

27

Id.

28

See NAT’L ACAD. SCIS., ENG’G & MED., MITOCHONDRIAL REPLACEMENT TECHNIQUES: ETHICAL,
SOCIAL, AND POLICY CONSIDERATIONS xv (2016); WATTS ET AL., supra note 25, at 19. But see
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Mitochondrial DNA is distinct from nuclear DNA.29 Mitochondria
constitute approximately 0.1% of total DNA in the body.30
Mitochondria are responsible for providing energy to the cell, so
mitochondrial mutations can result in symptoms in parts of the body
that require high amounts of energy like “the brain, heart, kidneys and
major muscle groups.”31 Mitochondrial transfer is largely praised for
its ability to target disease‐causing mutations.32 In mitochondrial
transfer, doctors replace defective mitochondria with donor
mitochondria.33
Mitochondrial transfer could be used to improve fertility
outcomes, but its greatest medical promise appears to lie in preventing
or lessening the incidence of mitochondrial disease.34 Due to the
complexities of mitochondrial inheritance, it is difficult to ascertain the
incidence of mitochondrial disease. In the United States, 1 in 5,000
people are affected by genetic mitochondrial disease.35 In the United
Kingdom, estimates show that 1 in 5,000 people are affected by
changes, often referred to as “mutations in mitochondrial
DNA…[which] … can affect many different tissues and, in its severest
form, is fatal in childhood.”36 In Australia, approximately 1 in 200
Shiyu Luo et al., Biparental Inheritance of Mitochondrial DNA in Humans, 115 PROCS.NAT’L
ACAD. SCIS. 13039, 13039 (2018) (noting “exceptional cases where paternal [mitochondrial
DNA] could be passed to the offspring.”).
29

See NAT’L ACAD. SCIS., ENG’G & MED., supra note 28, at xiv‐xv.

30

WATTS ET AL., supra note 25, at 19.

31

Id. at 21.

32

See id. at vii, 57‐58.

33

For an overview of the different methods of mitochondrial transfer, see Andres Caicedo et
al., Artificial Mitochondria Transfer: Current Challenges, Advances, and Future Applications 2017
STEM CELLS INT’L 1 (2017), https://www.hindawi.com/journals/sci/2017/7610414/.

34

Alice Park, A Baby Was Born with DNA From 3 People. Here’s How That’s Possible, TIME (April
11, 2019 5:02 PM), https://time.com/5569057/three‐parent‐baby‐dna/; Rob Stein, Clinic Claims
Success in Making Babies With 3 Parents’ DNA, NPR (June 6, 2018, 5:11 AM),
https://www.npr.org/sections/health‐shots/2018/06/06/615909572/inside‐the‐ukrainian‐
clinic‐making‐3‐parent‐babies‐for‐women‐who‐are‐infertile; Testimony of George Daley
before Australian Senate Community Affairs Legislation Committee, Fri., Aug. 6, 2021,
Mitochondrial Donation Reform (Maeve’s Law) Bill 2021, at 25‐26.

35

See
Mitochondrial
Diseases,
CLEVELAND
https://my.clevelandclinic.org/health/diseases/15612‐mitochondrial‐diseases
Feb. 3, 2022).

36

(last

CLINIC,
visited

Mary Herbert & Doug Turnbull, Mitochondrial Donation — Clearing the Final Regulatory Hurdle
in the United Kingdom, 376 NEW ENGL. J. MED. 171, 171 (2017).
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women carry “genetic mutation[s] that could potentially lead to
mitochondrial disease developing and 1 in 5,000 babies are born with
a severely disabling form of mitochondrial disease that can cause
death in infancy, childhood or adulthood.”37 In other words, in
Australia, approximately 56 children per year are born with a “severe
form of [Leigh syndrome or other mitochondrial disease].”38

B. Bioethical Background and Definitional Debate
Mitochondrial transfer is accompanied by many ethical, social,
and policy considerations which arise in discussions related to the
legalization and the safety of the technique, regardless of jurisdiction.39
In fact, “[a]t the 2014 FDA Cellular, Tissue, and Gene Therapies
Advisory Committee meeting, an FDA employee stated that ‘[t]he
FDA recognizes [that there are] moral, ethical, and social policy issues
related to genetic modification of eggs and embryos, and that these
issues have the potential to affect regulatory decisions’”—although the
employee did not explain exactly what the potential effect of these

37

AUSTRALIAN MITOCHONDRIAL DISEASE FOUNDATION (AMDF), Submission to Senate
Community Affairs References Committee, Science of Mitochondrial Donation and Related
Matters, [Submission no. 26], 9 May 2018, at 2.; SCIENCE & TECHNOLOGY AUSTRALIA (STA),
Submission to Senate Community Affairs References Committee, Science of Mitochondrial
Donation and Related Matters, [Submission no. 18], Mitochondrial Donation Law Reform
(Maeve’s Law) Bill 2021, at 3.

38

McPherson, supra note 12.

39

See, e.g., NAT’L ACAD. SCIS., ENG’G & MED., supra note 28, at 79–112; AUSTRALIAN GOV’T, NAT’L
HEALTH AND MED. RESEARCH, Mitochondrial Donation Law Reform (Maeve’s Law) Bill 2021,
[Submission no. 17], at 7–8 Council (“[Australian Health Ethics Committee] AHEC is the only
national body in Australia with statutory responsibilities for providing advice on ethical
issues related to health and for developing human research guidelines . . . The passage of
Maeve’s Law through the Australian Parliament would lead to important work for AHEC to
provide ongoing advice on the ethical implementation of mitochondrial donation. This would
include undertaking a limited and focused revision of the Ethical guidelines on the use of assisted
reproductive technology in clinical practice and research to incorporate guidance specifically on
the use of mitochondrial donation in Australian clinical practice.”).
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issues might be.40 Further, the agency did not convene a meeting to
discuss these issues and specifically prohibited such a discussion.41
Debates related to mitochondrial transfer are part of a broader
controversy over ART.42 Beyond “traditional” ART like in vitro
fertilization, there are conversations in multiple literatures related to
how reproductive rights and possibly society may be impacted by
gene modifying techniques.43 Issues in assisted reproductive
technology and genetic innovation also implicate the literatures of
equality, access, and disability rights.44
There is also a larger bioethical debate related to whether children
created using forms of assisted reproductive technology would have
existed but for the technology and the proper role of parents in

40

Transcript of Center for Biologics Evaluation and Research, U.S. Food & Drug Admin.,
Cellular, Tissue, and Gene Therapies Advisory Committee Meeting #59 (Feb. 25, 2014)
[hereinafter
Meeting
#59
Transcript],
at
13,
https://wayback.archive‐
it.org/7993/20170113010701/http://www.fda.gov/downloads/AdvisoryCommittees/Committ
eesMeetingMaterials/BloodVaccinesandOtherBiologics/CellularTissueandGeneTherapiesAd
visoryCo/UCM426293.pdf.

41

Lewis, How Subterranean Regulation Hinders Innovation in Assisted Reproductive Technology,
supra note 17, at 1273.

42

See supra notes 4‐9.

43

See, e.g., Sonia Suter, The ‘Repugnance’ Lens of Gonzales v. Carhart and Other Theories of
Reproducing Rights: Evaluating Advanced Reproductive Technologies, 76 GEO. WASH. L. REV. 1514,
1541–48, 1553 (2008); I. Glenn Cohen, The Constitution and the Rights Not to Procreate, 60 STAN.
L. REV. 1135, 1139–41, 1148‐65 (2008); CHRISTINE OVERALL & ARTHUR L. CAPLAN, WHY HAVE
CHILDREN? : THE ETHICAL DEBATE 19–33 (2012); Leon Kass, The Wisdom of Repugnance, THE
NEW REPUBLIC, June 2, 1997, at 24; Leon Kass, The Wisdom of Repugnance: Why We Should Ban
the Cloning of Humans, 32 VAL. U. L. REV. 679, 704 (1998); see generally John A. Robertson,
Genetic Selection of Offspring Characteristics, 76 B.U. L. REV. 421 (1996) (discussing the ethical
and legal implications of a number of technologies, including pre‐implantation genetic
diagnosis); John A. Robertson, Embryos, Families, and Procreative Liberty: The Legal Structure of
the New Reproduction, 59 S. CAL. L. REV. 939 (1986) (discussing “[t]he legal structure of the new
reproduction”).

44

Suter, supra note 43, at 1556–66 (2008); Vence L. Bonham & Lisa E. Smilan, Somatic Genome
Editing in Sickle Cell Disease: Rewriting a More Just Future, 97 N.C. L. REV. 1093, 1136–43 (2019);
NATURE BIOTECHNOLOGY, CRISPR GERMLINE ENGINEERING—THE COMMUNITY SPEAKS, 33
NATURE BIOTECH. 478, 481 (2015) (“in some instances, [like] correction of hearing deficits or
enhancement of stature—patient groups have argued that the ‘defect’ is a perfectly acceptable
form of human variation that should not be subjected to genetic cleansing.”); Courtney
Megan Cahill, Obergefell and the “New” Reproduction, 100 MINN. L. REV. HEADNOTES 1, 1, 11
(2016); Seema Mohapatra, Assisted Reproduction Inequality and Marriage Equality, 92 CHI. KENT
L. REV. 87, 88, 91‐97 (2017).
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selecting traits for children via assisted reproductive technology.45
Bioethicists and sociologists have substantially analyzed the impacts
of assisted reproductive technology and genetic modification on
identity.46 Issues related to identity accompany advanced assisted
reproductive technologies as bioethicists and the public ask whether
these techniques impact the identity of the children conceived using
these technologies. For many bioethicists, modifications of non‐
nuclear DNA are not viewed as modifying “identity.”47 Similarly,
there are concerns about parents’ ability to impact not only their
children, but future generations of children.48 This leads to arguments
based on hubris, sometimes from religious perspectives, in which
observers note that physicians are “playing God” and will lead society
down a “slippery slope” through actions involving genetic

45

See, e.g., DOV FOX, BIRTH RIGHTS AND WRONGS: HOW MEDICINE AND TECHNOLOGY ARE
REMAKING REPRODUCTION AND THE LAW 145 (2019) (citation omitted).

46

See sources cited supra note 34; see also Karinne Ludlow, Genetic Identity Concerns of Novel
Reproductive Techniques, J.L. & BIOSCI. 1, 2–3.

47

See Shoukhrat Mitalipov & Don P. Wolf, Clinical and Ethical Implications of Mitochondrial Gene
Transfer, 25 TRENDS ENDOCRINOL. METAB. 5, 7 (2014); Rob Stein, Her Son Is One of the Few
Children
to
Have
3
Parents’
DNA,
NPR
(June
6,
2018,
5:47
PM),
https://www.npr.org/sections/health shots/2018/06/06/616334508/her‐son‐is‐one‐of‐the‐few‐
children‐to‐have‐3‐parents. For sources supporting the idea that mitochondrial replacement
therapy does not affect identity; see HUM. FERTILISATION & EMBRYOLOGY AUTH.,
MITOCHONDRIA REPLACEMENT CONSULTATION: ADVICE TO GOVERNMENT 21 (2013),
https://www.hfea.gov.uk/media/2618/mitochondria_replacement_consultation_‐
_advice_for_government.pdf [hereinafter ADVICE TO GOVERNMENT]; see Jackie Leach Scully,
A Mitochondrial Story: Mitochondrial Replacement, Identity and Narrative, 31 BIOETHICS 37, 39
(2017) (noting that “social processes . . . form and maintain identity”); see generally Alexandra
Reznichenko et al., Mitochondrial Transfer: Ethical, Legal and Social Implications in Assisted
Reproduction, 8 S. AFR. J. BIOETHICS & L. 32, 33–34 (2015) (“Other kinship forms that challenge
the argument of loss of identity in children with ‘three’ parents include adoption, surrogacy
and use of donor gametes (sperm or oocytes alike) or gestational carriers.”); see Rosamund
Scott & Stephen Wilkinson, Germline Genetic Modification and Identity: The Mitochondrial and
Nuclear Genomes, 37 OXFORD J. LEGAL STUD. 886, 914 (2017) (discussing the impacts of
mitochondrial replacement therapies and nuclear genome editing on identity and offering
arguments on both sides of the identity alteration debate). But see A. L. Bredenoord et al.,
Ethics of Modifying the Mitochondrial Genome, 37 J. MED. ETHICS 97, 98–99 (2011); Calum
MacKellar, Genome Modifying Reproductive Procedures and Their Effects on Numerical Identity, 25
NEW BIOETHICS 121, 131 (2019).

48

Sarah Polcz & Anna Lewis, CRISPR‐CAS9 and the Non‐Germline Non‐Controversy, 3 J.L. &
BIOSCI. 413, 415 (2016); Sonia M. Suter, A Brave New World of Designer Babies?, 22 BERKELEY
TECH. L.J. 897, 963 (2007).
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modification which constitute a “step too far.”49 Others, including
religious groups, note that mitochondrial transfer and techniques that
can lead to the disposal of embryos “do not respect the human dignity
of embryos.”50 In previous works, I have argued that in spite of these
ethical objections, advanced assisted reproductive technologies
(“AARTs”) and germline gene editing should be treated similarly to
ART and thus regulated by states and not the federal government.51
Concerns over genetic modification are often heightened when
changes affect the “germline,” meaning that the changes are
inheritable by subsequent offspring. For example, the fact that
mitochondrial transfer made a change “at” the germline was the basis
for mitochondrial transfer’s prior illegality in the United Kingdom.52

49

See Clyde Haberman, Scientists Can Design ‘Better’ Babies. Should They?, N.Y. TIMES (June 10,
2018),
https://www.nytimes.com/2018/06/10/us/11retro‐baby‐genetics.html;
David
Warmflash, Religious Beliefs Shape Our Thinking on Cloning, Stem Cells, and Gene Editing,
GENETIC
LITERACY
PROJECT
(Nov.
27,
2019),
https://geneticliteracyproject.org/2019/11/27/religious‐beliefs‐shape‐our‐thinking‐on‐
cloning‐stem‐cells‐and‐gene‐editing/; Rob Stein, House Committee Votes to Continue Ban On
Genetically Modified Babies, NPR (Jun. 4, 2019, 4:38 PM) https://www.npr.org/sections/health‐
shots/2019/06/04/729606539/house‐committee‐votes‐to‐continue‐research‐ban‐on‐
genetically‐modified‐babies; Agneta Sutton, A Case Against Germ‐Line Gene Therapy, 29 ETHICS
& MED. 17, 20–22 (2013); James J. Walter, Theological Issues in Genetics, 60 THEOLOGICAL STUD.
124, 129–132 (1999); Marc A. Thiessen, Gene Editing Is Here. It’s an Enormous Threat., WASH.
POST (Nov. 29, 2018), https://www.washingtonpost.com/opinions/gene‐editing‐is‐here‐its‐
an‐enormous‐threat/2018/11/29/78190c96‐f401‐11e8‐bc79‐68604ed88993_story.html; Michael
J.
Sandel,
The
Case
Against
Perfection,
THE
ATLANTIC
(Apr.
2004),
https://www.theatlantic.com/magazine/archive/2004/04/the‐case‐against‐perfection/302927/;
Chi C. Wong & Martin H. Johnson, Therapy for Mitochondrial Genetic Disease: Are We at the Thin
End of the Wedge?, 29 REPROD. BIOMED. ONLINE 147, 148 (2014); William Gardner, Can Human
Genetic Enhancement Be Prohibited?, 20 J. MED. & PHIL. 65, 65–67 (1995); Erik Parens, Should We
Hold the (Germ) Line?, 23 J.L. MED. & ETHICS 173, 174, 176 (1995); Marcy Darnovsky, A Slippery
Slope to Human Germline Modification, 499 NATURE 127, 127 (2013); Tony McGleenan, Human
Gene Therapy and Slippery Slope Arguments, 21 J. MED. ETHICS 350, 350 (1995); NAT’L ACAD.
SCIS., ENG’G & MED., supra note 28, at 7. But see Kenan Malik, Opinion, The Three‐Parent Baby’s
First Step, N.Y. TIMES (Feb. 22, 2015), http://www.nytimes.com/2015/02/23/opinion/the‐three‐
parent‐babys‐first‐step.html.

50

THE SENATE CMTY. AFFS. LEGIS. COMM., Mitochondrial Donation Law Reform (Maeve’s Law) Bill
2021 [Provisions], Aug. 2021, at 31 [hereinafter Maeve’s Law Provisions].

51

See, e.g., Lewis, How Subterranean Regulation Hinders Innovation in Assisted Reproductive
Technology, supra note 17, at 1259‐262; Myrisha S. Lewis, Is Germline Gene Editing Exceptional?,
51 SETON HALL L. REV. 735 (2020).

52

For an analysis of U.K. law’s distinctions between “germline modification,” “germline genetic
modification,” and “genetic modification,” ultimately culminating in the legal permissibility
of mitochondrial transfer procedures, see Scott & Wilkinson, supra note 47, at 886–87, 891, 897–
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The use of techniques involving heritable genetic modifications in the
United States are stymied by the recent recurring budget rider.53
Some argue that all uses of mitochondrial transfer constitute a
change to the human germline. whereasOthers argue that because
mitochondria are maternally inherited, only the use of modified
female embryos constitutes a human germline modification.54 Some
note that techniques like mitochondrial transfer involve a germline
modification but not in the same way as germline gene editing as those
AARTs involve the modification of non‐nuclear DNA, which
differentiates them from germline gene editing.55 Others argue that
mitochondrial DNA are insignificant and thus not part of a germline
modification.56 Some even contest the idea that mitochondrial transfer
is “genetic manipulation” at all.57
An Institute of Medicine panel, convened to study mitochondrial
replacement techniques at the FDA’s request, concluded that
mitochondrial replacement is not heritable genetic modification.58 This
conclusion partly rested on the widely‐accepted belief that
mitochondria are maternally transmitted; for this reason, the National

904.
53

See discussion in Part II infra.

54

See Scott & Wilkinson, supra note 47 (referencing NAT’L ACAD.
MITOCHONDRIAL REPLACEMENT TECHNIQUES (2016)).

55

See Viswanathan, supra note 11(quoting Eli Adashi, M.D.: “[Mitochondrial replacement
therapy] can technically be construed as germline modification, so mitochondrial
replacement got swept up into that [Congressional budget] rider. It was caught up in the gene
editing concerns, and I think it’s sort of an unfortunate linkage.”); Eli Y. Adashi & I. Glenn
Cohen, Going Germline: Mitochondrial Replacement as a Guide to Genome Editing, 164 CELL 832,
833 (2016).

56

Ainsley J. Newson & Anthony Wrigley, Is Mitochondrial Donation Germ‐Line Gene Therapy?
Classifications and Ethical Implications, 31 BIOETHICS 55, 58 (2017) (citing PUBLIC HEALTH
DIRECTORATE/HEALTH SCIENCE AND BIOETHICS DIVISION, MITOCHONDRIAL DONATION: A

OF

SCIS., ENG’G & MED.,

CONSULTATION ON DRAFT REGULATIONS TO PERMIT THE USE OF NEW TREATMENT TECHNIQUES TO
PREVENT THE TRANSMISSION OF A SERIOUS MITOCHONDRIAL DISEASE FROM MOTHER TO CHILD

(2014) and observing “[t]he implication here being that if a change is not significant, it does
not constitute gene therapy (of any kind).”).
57

Emerging Mitochondrial Therapies and Their Ethicality, HARV. SCI. REV. (Dec. 09, 2018),
https://harvardsciencereview.org/2018/12/09/emerging‐mitochondrial‐therapies‐and‐their‐
ethicality/.

58

NAT’L ACAD. SCIS., ENG’G & MED., supra note 28, at 88 (“This committee . . . views ‘genetic
modification’ and ‘germline modification’ as two separate concepts, the first being ‘changes
to the genetic material within a cell’ and the latter ‘human inheritable genetic modification.’”).
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Academies of Sciences recommended that only male embryos be
initially selected if mitochondrial transfer was used in the United
States.59 The ISSCR also maintains that there is a difference between
mitochondrial replacement therapy (MRT) and heritable genome
editing and that MRT research and clinical use should be permissible.60
The ISSCR’s position does not include a sex‐based caveat or
recommendation.61 The next Part details regulatory responses in the
U.S., U.K., and Australia to the bioethical considerations that
accompany MRT.

II. Regulation of ART and Mitochondrial Transfer in the
United States, United Kingdom, and Australia
The similarities between the U.S., U.K., and Australia render the
potential lessons from those countries applicable to the United States.
First, as alluded to in the Article’s title, all three are classified as
“common law countries.”62 Second, while the U.K. and Australia are
most similar, all three countries’ governments contain federal
structures.63 Third, in vitro fertilization is legal in all three counties,
albeit under differing regulatory regimes.64 Fourth, each country was
an early user of in vitro fertilization; the first babies born in the United

59

See id. at xv. But see Luo et al., supra note 28, at 13939 (noting “exceptional cases where paternal
[mitochondrial DNA] could be passed to the offspring.”).

60

Maeve’s Law Provisions, supra note 50, at 39.

61

Id.

62

Foreign
Legal
Research
Guide,
PRITZKER
LEG.
RSCH.
CTR.,
https://library.law.northwestern.edu/Foreign/legalsystems (last visited Dec. 14, 2021)
(“Examples of common law countries include the United States, Australia, and the United
Kingdom (except for Scotland, Guernsey, and Jersey).”); The Common Law and Civil Law
Traditions,
BERKELEY
LAW:
THE
ROBBINS
COLLECTION
1,
5,
https://www.law.berkeley.edu/research/the‐robbins‐collection/exhibitions/common‐law‐
civil‐law‐traditions/.

63

Steven G. Calabresi, Does Institutional Design Make A Difference?, 109 NW. U. L. REV. 577, 582–
83 (2015).

64

The U.K. and Australia have centralized regimes for accessing in vitro fertilization, whereas
the United States has been categorized as “the Wild Wild West.” See Alexander N. Hecht, The
Wild Wild West: Inadequate Regulation of Assisted Reproductive Technology, 1 HOUS. J. HEALTH L.
& POL’Y 227, 228 (2001).
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Kingdom (and the world), Australia, and the United States as a result
of IVF, were born in 1978, 1980, and 1981, respectively.65
In the American legal literature, analysis of assisted reproductive
technology tends to focus on the lack of regulation of assisted
reproductive technology in the U.S. and how this lack of regulation
stands in stark contrast to the U.K.’s robust system for ART regulation
through the Human Fertilisation & Embryology Authority.66 Similarly,
accounts in multiple literatures focus on the first child born as a result
of in vitro fertilization, Louise Brown, in July 1978 in the United
Kingdom, along with the publication of the results of the Warnock
Committee’s report.67 The Warnock Committee Report shows that
public consideration of the moral, ethical, and social issues have
existed since the early days of IVF in the U.K.68 Yet, these accounts
often leave out innovations in Australia. For example, Australia
funded IVF research “and by 1984, the team at Monash University in
Melbourne had overtaken the UK as the world‐leader with a series of
other firsts, including twins, triplets, babies born from donor eggs and

65

See
The
American
Experience,
PBS,
https://www.pbs.org/wgbh/americanexperience/features/babies‐americas‐first/;
Elizabeth
Simpson, America’s 1st test‐tube baby, a Norfolk native, set to meet world’s 1st test‐tube baby (Mar.
3, 2017, 6:00 PM), https://www.pilotonline.com/news/health/article_17303144‐c2b8‐55e2‐
8669‐11d42d894fc6.html; History, Timeline, MONASH IVF, https://monashivf.com/why‐
monash‐ivf/history/; https://www.marieclaire.com.au/candice‐thum‐australia‐first‐ivf‐baby‐
birthday.

66

Ellen S. Fischer, The ‘Wild West’ of Medicine: An Argument for Adopting the United Kingdom’s
‘HFEA’ Framework, to Improve the Market for Assisted Reproduction in the United States, 39 NW. J.
INT’L L. & BUS. 201, 203–04, 217 (2019); Alicia Ouellette et al., Lessons Across the Pond: Assisted
Reproductive Technology in the United Kingdom and the United States, 31 B.U. AM. J. L. & MED.
419, 419, 423, 430, 434–35 (2005).

67

See DEP’T HEALTH & SOC. SEC., REPORT OF THE COMMITTEE OF INQUIRY INTO HUMAN
FERTILISATION
&
EMBRYOLOGY,
1984,
HC
9314
(UK),
https://www.hfea.gov.uk/media/2608/warnock‐report‐of‐the‐committee‐of‐inquiry‐into‐
human‐fertilisation‐and‐embryology‐1984.pdf; Natasha Hammond‐Browning, Ethics,
Embryos, and Evidence: A Look Back at Warnock, 23 OXFORD MED. L. REV. 588, 588–619 (2015);
Katharine Dow, ‘The Men Who Made The Breakthrough’: How the British Press Represented Patrick
Steptoe and Robert Edwards in 1978, 4 REPROD. BIOMED. & SOC’Y ONLINE 59, 59–67 (2017); Jody
Schechter, Promoting Human Embryonic Stem Cell Research: A Comparison of Policies in the United
States and the United Kingdom and Factors Encouraging Advancement, 45 TEX. INT’L L.J. 603, 614–
16 (2010); Margaret Foster Riley & Richard A. Merrill, Regulating Reproductive Genetics: A
Review of American Bioethics Commissions and Comparison to the British Human Fertilisation and
Embryology Authority, 6 COLUM. SCI. & TECH. L. REV. 1, 103, 105, 110–114 (2001).

68

See DEP’T HEALTH & SOC. SEC., supra note 67.
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frozen embryos.”69 Today, the U.K. has arguably regained its position
as the world leader in ART with its legalization of mitochondrial
transfer. Australia is following as it lays the groundwork for the
potential clinical use of mitochondrial transfer, while the United States
remains in a regulatory standstill, despite the progress made in the
U.S. related to the underlying science of mitochondrial transfer.70

A. United States
Although the practice of medicine is mostly regulated by the
states, the FDA has blocked the use of mitochondrial transfer and other
related techniques by asserting jurisdiction over them.71 Over the past
20 years, the federal legal system discouraged the use of mitochondrial
transfer in the United States as evidenced by the issuance of Untitled
Letters to physician‐researchers engaged in both mitochondrial

69

Michael Morrison & Stevienna de Saille, CRISPR in Context: Towards a Socially Responsible
Debate on Embryo Editing, PALGRAVE COMMC’NS (Sept. 2019), at 4 (citing Harry Kannegiesser,
CONCEPTION IN THE TEST TUBE: THE IVF STORY: HOW AUSTRALIA LEADS THE WORLD (Macmillan
Australia 1988)).

70

See Viswanathan, supra note 11; see, e.g., Ariana Eunjung Cha, This Fertility Doctor is Pushing
the Boundaries of Human Reproduction, with Little Regulation, WASH. POST: HEALTH & SCI. (May
14, 2018, 7:00 AM), https://www.washingtonpost.com/national/health‐science/this‐fertility‐
doctor‐is‐pushing‐the‐boundaries‐of‐human‐reproduction‐with‐little‐
regulation/2018/05/11/ea9105dc‐1831‐11e8‐8b08‐027a6ccb38eb_story.html; Jill Neimark, A
Baby with 3 Genetic Parents Seems Healthy, but Questions Remain, NPR: TREATMENTS (Apr. 8,
2017, 5:00 AM), https://www.npr.org/sections/health‐shots/2017/04/08/523020895/a‐baby‐
with‐3‐genetic‐parents‐seems‐healthy‐but‐questions‐remain; Michelle Roberts, First ‘Three
Person
Baby’
Born
Using
New
Method,
BBC NEWS
(Sept.
27,
2016),
https://www.bbc.com/news/health‐37485263; Robinson, supra note 7; Giselle Lee, Shoukhrat
Mitalipov and Masahito Tachibana’s Mitochondrial Gene Replacement Therapy Technique, THE
EMBRYO PROJECT ENCYCLOPEDIA (Sept. 6, 2017), https://embryo.asu.edu/pages/shoukhrat‐
mitalipov‐and‐masahito‐tachibanas‐mitochondrial‐gene‐replacement‐therapy‐technique.

71

See Therapeutic Cloning and Genome Modification, Cellular & Gene Therapy Products, U.S. FOOD &
DRUG
ADMIN.
(Mar.
16,
2018),
https://www.fda.gov/biologicsbloodvaccines/cellulargenetherapyproducts/ucm2007205.htm
(“In March 2001, FDA sent a letter to the research community asserting regulatory authority
over clinical research using cloning technology to create a human being, and to advise that
FDA regulatory process is required in order to initiate these investigations. FDA jurisdiction
includes human cells used in therapy involving the transfer of genetic material by means
other than the union of gamete nuclei. Examples of such genetic material include, but are not
limited to: cell nuclei (for cloning), oocyte nuclei, ooplasm, which contains mitochondria and
genetic material contained in a genetic vector, transferred to gametes or other cells. Any
clinical research involving these techniques would require an IND.”).
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transfer and techniques similar to mitochondrial transfer.72 These
FDA‐issued Untitled Letters and “advisories” fall short of official
enforcement actions but nonetheless discourage physicians and
scientists from using and researching techniques involving
reproductive genetic innovation and also human reproductive
cloning, an idea that generated an extensive uproar in the 1990s and
early 2000s.73
The FDA has posted an advisory online, listing the techniques that
it proclaims require an investigational new drug (IND) application
even though these techniques involve the practice of medicine, which
is regulated by states and not the federal government.74 The FDA’s
online advisory applies to a number of techniques, including
mitochondrial transfer, germline gene editing, and cytoplasmic
transfer.75
In 2015, approximately five years into the FDA’s subterranean
regulation of techniques involving reproductive genetic innovation,
Congress added an appropriations rider to the 2016 budget to prevent
the FDA from using funds on the aforementioned IND applications
involving heritable genetic modification.76 The rider, which was
accompanied by little substantive discussion in Congress, reads:

72

For a general overview of the FDA’s pattern of using guidance documents (including online
advisories) and Untitled Letters, see generally sources cited, supra note 17; see also Issues Raised
by Human Cloning Research: Hearing Before the H. Subcomm. on Oversight and Investigations of the
Comm. on Energy and Commerce, 107th Cong. 78–81 (2001) (providing the statement of Kathryn
C. Zoon, Dir. of Ctr. for Biologics Evaluation & Research, U.S. Food & Drug Admin.); Stuart
L. Nightingale, Letter About Human Cloning, U.S. FOOD & DRUG ADMIN. (Oct. 26, 1998),
http://www.fda.gov/ScienceResearch/SpecialTopics/RunningClinicalTrials/ucm150508.htm.

73

See supra note 72 and accompanying text.

74

See FDA Regulation of Human Cells, Tissues, and Cellular and Tissue‐Based Products (HCT/P’s)
Product List, U.S. FOOD & DRUG ADMIN. (Feb. 1, 2018), https://www.fda.gov/vaccines‐blood‐
biologics/tissue‐tissue‐products/fda‐regulation‐human‐cells‐tissues‐and‐cellular‐and‐tissue‐
based‐products‐hctps‐product‐list [https://perma.cc/B3HK‐BBW3] [hereinafter Product List].
In prior works, I have argued that the FDA’s declaration exceeded its jurisdiction. See generally
sources cited, supra note 17; Myrisha S. Lewis, Innovating Federalism in the Life Sciences, 92
TEMPLE L. REV. 383, 391–402 (2020) (discussing the practice‐products divide in medical
innovation).

75

See Product List, supra note 74.

76

Russell A. Spivak et al., Germ‐line Gene Editing and Congressional Reaction in Context: Learning
from Almost 50 Years of Congressional Reactions to Biomedical Breakthroughs, 30 J.L. & HEALTH 20,
21–22 (2017); Consolidated Appropriations Act of 2016, Pub. L. No. 114‐113, § 749, 129 Stat.
2283, 2283 (2015).
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None of the funds made available by this Act may be used to
notify a sponsor or otherwise acknowledge receipt of a
submission for an exemption for investigational use of a drug
or biological product under section 505(i) of the Federal Food,
Drug, and Cosmetic Act (21 U.S.C. 355(i)) or section 351(a)(3)
of the Public Health Service Act (42 U.S.C. 262(a)(3)) in
research in which a human embryo is intentionally created or
modified to include a heritable genetic modification. Any such
submission shall be deemed to have not been received by the
Secretary, and the exemption may not go into effect.77
That rider has been renewed every subsequent year.78 Thus, even
though both the FDA’s informal regulation and Congress’ recent
recurring budget rider have both been unaccompanied by substantial
legal explanation, it is likely that public deliberation will be necessary
to change the regulatory treatment of mitochondrial transfer.
This regulatory treatment has not prevented some U.S.‐based
physicians from traveling abroad to provide the technique to patients
in countries with more favorable regulatory climates.79 For example,
the U.S.‐based physician, Dr. John Zhang traveled to Mexico to

77

Consolidated Appropriations Act of 2016, H.R. 2029, 114th Cong. (2015) [hereinafter CAA]
(prohibiting the FDA from consider applications involving “heritable genetic modification.”).
While the budget rider focuses on a clinical investigation and the domestic creation of a
“genetically modified embryo,” neither the budget rider nor the FDA’s letter to Dr. John
Zhang addresses the potential role of foreign clinical trials in support of a BLA or IND
application. See Letter from Mary A. Malarkey, Dir., Off. of Compliance & Biologics Quality,
Trustee for Biologics Evaluation & Rsch., to John Zhang, Chief Exec. Officer, Darwin Life, Inc.
& New Hope Fertility Ctr., FDA (Aug. 4, 2017) [hereinafter Letter from Mary A. Malarkey],
https://www.fda.gov/media/106739/download [https://perma.cc/5PEC‐8RZP]; U.S. FOOD &
DRUG ADMIN., Guidance for Industry and FDA Staff: FDA Acceptance of Foreign Clinical Studies
Not Conducted Under an IND: Frequently Asked Questions (March 2012),
https://www.fda.gov/files/about%20fda/published/FDA‐Acceptance‐of‐Foreign‐Clinical‐
Studies‐Not‐Conducted‐Under‐an‐IND—Frequently‐Asked‐Questions.pdf;
Anna
M.
O’Connell et al., Global Approaches to Drug Development: When Ex‐US Clinical Data Can Support
US Drug Approvals, IQVIA, https://www.iqvia.com/‐/media/iqvia/pdfs/library/white‐
papers/global‐approaches‐to‐drug‐development.pdf (last visited Nov. 16, 2021); 21 C.F.R. §
314.106 (2022).

78

Spivak et al., supra note 76, at 21‐22; see CAA, supra note 77 (rider text and accompanying
text).

79

See, e.g., Roberts, supra note 70.
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provide the technique to a couple who wanted to avoid transmitting
Leigh’s syndrome to their children.80 Providing the technique in
Mexico allowed Dr. Zhang, his team, and the intended parents to
avoid the limitations of the U.S. regulatory system.81 After providing
mitochondrial transfer in Mexico and requesting a pre‐IND meeting
with the FDA, Dr. John Zhang was informed by letter that the FDA
could not consider its application due to the congressional budget
rider.82
Dr. Shoukhrat Mitalipov of the Oregon Health Sciences University
has achieved mitochondrial transfer in rhesus macaques; however, the
use of this techniques in human pregnancies has not yet occurred.83 In
2015, Mitalipov confirmed that he had submitted two applications to
the FDA for clinical trials related to mitochondrial transfer.84 While Dr.
Mitalipov predicted a potential year‐long delay by the FDA in order to

80

See, e.g., id.; Ariana Eunjung Cha, This Fertility Doctor is Pushing the Boundaries of Human
Reproduction, with Little Regulation, WASH. POST (May 14, 2018, 7:00 AM),
https://www.washingtonpost.com/national/health‐science/this‐fertility‐doctor‐is‐pushing‐
the‐boundaries‐of‐human‐reproduction‐with‐little‐regulation/2018/05/11/ea9105dc‐1831‐
11e8‐8b08‐027a6ccb38eb_story.html; Neimark, supra note 70.

81

See, e.g., Neimark, supra note 70. See Jessica Hamzelou, Exclusive: World’s First Baby Born with
New
“3
Parent”
Technique,
NEW
SCIENTIST
(Sept.
27,
2016),
https://www.newscientist.com/article/2107219‐exclusive‐worlds‐first‐baby‐born‐with‐new‐
3‐parent‐technique/ (“Neither [mitochondrial transfer] method has been approved in the US,
so Zhang went to Mexico instead, where he says ‘there are no rules.’”). While this Article
focuses on strides in mitochondrial DNA research as applied to reproductive genetic
innovation, research in mitochondrial DNA outside of reproduction continues. See, e.g.,
UCLA HEALTH SCIS., Scientists Develop High‐Throughput Mitochondria Transfer Device, SCI.
DAILY (Dec. 29, 2020), https://www.sciencedaily.com/releases/2020/12/201229140838.htm.
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See Letter from Mary A. Malarkey, supra note 77, at 1.
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See Robinson, supra note 7; Lee, supra note 70.

84

Steve Connor, Scientist Who Pioneered ‘Three‐Parent’ IVF Embryo Technique Now Wants to Offer
it to Older Women Trying for a Baby, THE INDEPENDENT (Feb. 8, 2015,
https://www.independent.co.uk/news/science/threeparent‐embryos‐an‐ivf‐revolution‐or‐a‐
slippery‐slope‐to‐designer‐babies‐10031477.html (“Professor Mitalipov, who has advised
Britain’s Human Fertilisation and Embryology Authority (HFEA) on mitochondrial transfer,
confirmed he has applied to the FDA for two clinical trials licences, one for treating
mitochondrial disease, the other for treating age‐related infertility. ‘It’s all one package,’ he
said. ‘We use the same treatment for mitochondrial disease patients, and, separately, another
trial will be for women of advanced age.’ ‘They may approve one procedure first and then a
second. That’s my expectation,’ he said. ‘So far we haven’t heard anything from the FDA on
the specifics of how they want us to run this clinical trial. My sense is that they want to take
the route that the HFEA did. ‘They want to maybe look first into ethics,’ he added. ‘I think
we’re talking of another year of delay.’”).
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consider ethical issues related to mitochondrial transfer, the recent
trajectory of U.S. restrictions means that predicted year‐long delay is
continuing to grow.85 For example, as indicated by the FDA’s 2017
letter to Dr. John Zhang, in spite of objections by many scientists, the
FDA has interpreted a recuring Congressional budget rider preventing
the agency from using funds on applications involving “heritable
genetic modification” to encompass mitochondrial transfer, thus
stymying innovation related to mitochondrial transfer in the U.S.86
Moral views have shaped legislation and regulatory decisions and will
continue to do so.87 Currently, concerns about embryo destruction,
“playing God,” possibly harming future children using germline gene
editing, the possibility of using enhancement for gene editing, and the
idea of changing the gene pool have been proffered as possible
rationales underlying the current budget rider prohibiting FDA‐
consideration of IND applications involving heritable genetic
modification in the United States.88

B. United Kingdom
The United Kingdom has played an important role in the
development of assisted reproductive technology. The first child in the
world born as a result of in vitro fertilization, Louise Brown, was born
in the U.K.89 The Human Fertilisation & Embryology Authority
(HFEA) “is the UK’s independent regulator of treatment using eggs
and sperm, and of treatment and research involving human

85

Id.

86

See Letter from Mary A. Malarkey, supra note 77, at 1; Spivak et al., supra note 76, at 21‐22;
Consolidated Appropriations Act of 2016, Pub. L. No. 114‐113, § 749, 129 Stat. 2283, 2283
(2015) (prohibiting the FDA from considering applications involving heritable genetic
modification).

87

Seema Mohapatra, Politically Correct Eugenics, 12 FIU L. REV. 51, 54 (2016) (noting “the effect
of eugenic ideals in the legislative policies of the United States” including immigration and
anti‐miscegenation laws).

88

I. Glenn Cohen, Circumvention Medical Tourism and Cutting‐Edge Medicine: The Case of
Mitochondrial Replacement Therapy, 25 IND. J. GLOB. LEGAL STUD. 439, 453–54 (2018) (noting the
scant legislative history accompanying the budget rider which prohibits FDA consideration
of techniques involving heritable genetic modification); Stein, supra note 49.

89

Press Release, The Nobel Assembly at Karolinska Institute, The Nobel Prize in Physiology or
Medicine 2010 (Oct. 4, 2010), https://www.nobelprize.org/prizes/medicine/2010/press‐
release/ [https://perma.cc/CK2M‐NNJE].
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embryos.”90 As such, the HFEA is responsible for a number of tasks
including licensing individual fertility clinics and research centers and
“…regulat[ing] the storage of gametes and embryos…”91 As of the
HFEA’s last annual report, released in November 2021, 103 clinics
were licensed by the HFEA to provide fertility treatment.92 Sixteen
additional licenses permitted research involving human embryos and
fourteen additional licenses provided for storage of gametes and
embryos only.93 In addition to licensing, the HFEA also publishes
guidelines for fertility providers.94
After a lengthy legalization process that included multiple public
consultations, multiple scientific reviews, and extensive scientific and
bioethical support, the UK legalized mitochondrial transfer in 2015.95

90

About Us, HUMAN FERTILISATION & EMBRYOLOGY AUTH., https://www.hfea.gov.uk/about‐us.

91

See Annual Report and Accounts 2012/13, HUMAN FERTILISATION & EMBRYOLOGY AUTH., 1, 8–9
(2013),
https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_d
ata/file/246699/0323.pdf [hereinafter 2013 ANNUAL REPORT]; Human Fertilisation and
Embryology Act, 1990, c. 37, §§ 5‐10 (Eng.); Steve P. Calandrillo & Chryssa V. Deliganis, In
Vitro Fertilization and the Law: How Legal and Regulatory Neglect Compromised A Medical
Breakthrough, 57 ARIZ. L. REV. 311, 333 (2015); About Us, supra note 90; HUM. FERTILISATION &
EMBRYOLOGY AUTH., supra note 10.

92

State of the Fertility Sector 2020/2021, HUM. FERTILISATION & EMBRYOLOGY AUTH. (Nov. 2021),
http://www.hfea.gov.uk/about‐us/publications/research‐and‐data/state‐of‐the‐fertility‐
sector‐2020‐2021/.

93

Id.; Applying for a Clinic License, HUM. FERTILISATION & EMBRYOLOGY AUTH.,
https://www.hfea.gov.uk/about‐us/applying‐for‐a‐clinic‐licence/.

94

HUM. FERTILISATION & EMBRYOLOGY AUTH., CODE OF PRACTICE 11 (9th ed. 2019),
https://www.hfea.gov.uk/media/2793/2019‐01‐03‐code‐of‐practice‐9th‐edition‐v2.pdf.

95

See Shoot, supra note 5. For the “three scientific reviews” of mitochondrial transfer (and the
2014 addendum to the “further update in 2014”), see generally HUM. FERTILISATION &
EMBRYOLOGY AUTH., ANNEX VIII: SCIENTIFIC REVIEW OF THE SAFETY AND EFFICACY OF METHODS
TO AVOID MITOCHONDRIAL DISEASE THROUGH ASSISTED CONCEPTION: UPDATE (2013),
https://www.hfea.gov.uk/media/2612/mito‐annex_viii‐science_review_update.pdf;
HUM.
FERTILISATION & EMBRYOLOGY AUTH., REVIEW OF THE SAFETY AND EFFICACY OF POLAR BODY
TRANSFER TO AVOID MITOCHONDRIAL DISEASE ADDENDUM TO ‘THIRD SCIENTIFIC REVIEW OF THE
SAFETY AND EFFICACY OF METHODS TO AVOID MITOCHONDRIAL DISEASE THROUGH ASSISTED
CONCEPTION: 2014 UPDATE’ (2014), https://www.hfea.gov.uk/media/2610/2014‐10‐07_‐
_polar_body_transfer_review_‐_final.pdf; HUM. FERTILISATION & EMBRYOLOGY AUTH.,
SCIENTIFIC REVIEW OF THE SAFETY AND EFFICACY OF METHODS TO AVOID MITOCHONDRIAL
DISEASE
THROUGH
ASSISTED
CONCEPTION
(2011),
https://www.hfea.gov.uk/media/2613/scientific‐review‐of‐the‐safety‐and‐efficacy‐of‐
methods‐to‐avoid‐mitochondrial‐disease‐through‐assisted‐conception.pdf;
HUM.FERTILISATION & EMBRYOLOGY AUTH., THIRD SCIENTIFIC REVIEW OF THE SAFETY AND
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In the United Kingdom, an HFEA‐issued license to provide the
technique is required and the technique is limited to disease causing
mutations.96 Only two mitochondrial transfer techniques are permitted
in the U.K.: maternal spindle transfer and pronuclear transfer.97 In
addition to licensing, the HFEA also approves the individual patients
who would receive mitochondrial donation therapy. 98 Currently, the
Newcastle Fertility Centre at Life has the sole license for research and
treatment of patients using approved mitochondrial donation
techniques in the U.K.99 In 2018, the HFEA approved the Newcastle
Fertility Centre’s use of mitochondrial donation for two women.100 So
far, no live births have been reported.101

C. Australia
In July 1978, when Robert Edwards and Patrick Steptoe
announced the birth of Louise Brown, the first baby born as a result of
using IVF, researchers in Melbourne were “devastated” to have not
achieved this milestone first.102 Instead, the first baby born as a result

EFFICACY OF METHODS TO AVOID MITOCHONDRIAL DISEASE THROUGH ASSISTED CONCEPTION:
2014
UPDATE,
at
4,
12
(2014),
https://www.hfea.gov.uk/media/2614/third_mitochondrial_replacement_scientific_review.p
df; Parliament Should Approve Regulations for Mitochondrial Donation, THE GUARDIAN (Jan. 30,
2015),
https://www.theguardian.com/science/2015/jan/30/parliament‐should‐approve‐
regulations‐for‐mitochondrial‐donation.
96

See HUM. FERTILISATION & EMBRYOLOGY AUTH., supra note 10 (“[Anyone] considering
mitochondrial donation treatment . . . should consult Newcastle Fertility Centre at Life . . .. If
they think you are eligible for treatment, they need to apply to [the Human Fertilization &
Embryology Authority] for permission [for treatment]. This is because [the Authority] need[s]
to approve every case of mitochondrial donation treatment to make sure it’s only done in a
legal and ethical way”); About Us, supra note 90; see infra discussion in Part III.

97

HUM. FERTILISATION & EMBRYOLOGY AUTH., supra note 10.

98

Id.

99

Id.

100

Doctors Given Approval for UK’s First ‘Three‐Person Babies’, BBC (Feb. 2, 2018),
https://www.bbc.com/news/health‐42918341.

101

See, e.g., I. Glenn Cohen et al., The Regulation of Mitochondrial Replacement Techniques Around
the World, 21 ANN. REV. GENOMICS HUM. GENETICS 565, 568 (2020).
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HARRY KENNEGIESSER, CONCEPTION IN THE TEST TUBE THE IVF STORY: HOW AUSTRALIA LEADS
(Macmillan 1988).
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of IVF in Australia was born in 1980.103 After much public discussion
and Parliamentary action, Maeve’s law is now in effect in Australia.104
After the law passed both houses of the Australian Parliament on
March 31, 2022, the Australian National Health and Medical Research
Council posted an announcement on April 10, 2022 for the 2022 Pilot
Mitochondrial Donation Pilot Program Grant Opportunity, which
aims to “support one Australian medical research and medical
innovation project that conducts a pilot program, including a clinical
trial, for the purposes of building the evidence base to determine the
safety, efficacy and feasibility of implementing mitochondrial
donation reproductive technology in clinical practice settings.”105
Australia is a federal constitutional state.106 It is composed of nine
jurisdictions including the Commonwealth of Australia, six states, and
two territories.107 While Australia has a federal structure in which ART
regulation comes from both federal and state sources, only four of the
eight Australian states and territories have their own ART

103

Ludlow, supra note 46, at 5‐6 (2020) (citing John Leeton, The Early History of IVF in Australia
and its Contribution to the World, AUSTL. & N.Z. J. OBSTETRICS & GYNAECOLOGY 495, 496 (2004)).

104

See AUSTL. GOV’T, DEP’T HEALTH, Legalising Mitochondrial Donation in Australia, Public
Consultation
Paper,
https://consultations.health.gov.au/strategic‐policy/mitochondrial‐
donation‐in‐
australia/supporting_documents/Mitochondrial%20Donation%20%20Public%20Consultatio
n%20Paper.pdf (requesting public comments by Mar. 15, 2021 and noting that “[t]he
Australian Government is proposing to introduce mitochondrial donation in a staged and
closely monitored way.”); Mitochondrial Donation, supra note 16..

105

Media Release, Australian Dep’t of Health & Aged Care, Australian Research to Support
Children
With
Mitochondrial
Disease
(Apr.
11,
2022),
https://www.health.gov.au/ministers/the‐hon‐greg‐hunt‐mp/media/australian‐research‐to‐
support‐children‐with‐mitochondrial‐disease; Bulletin from Austln. Gov’t Nat’l Health &
Medical Resource Council, 2022 Mitochondrial Donation Pilot Program Grant Opportunities
(Apr. 10, 2022), https://www.bulletpoint.com.au/wp‐content/uploads/2022/06/MRFF‐
EPCDRI‐2022‐Mitochondrial‐Donation‐Pilot‐Program‐Grant‐Opportunity‐Guidelines.pdf;
Aus. Gov’t, Archived Grant Opportunity View – GO5600, Apr. 10, 2022,
https://www.grants.gov.au/Go/Show?GoUuid=46103a3e‐81c5‐49c2‐89ce‐ddd710e4684d.

106

Carol A. Brook et al., A Comparative Examination of Police Interrogation of Criminal Suspects in
Australia, Canada, England and Wales, New Zealand, and the United States, 29 WM. & MARY BILL
RTS. J. 909, 911 (2021).

107

Id.; AUSTL. GOV’T, State and Territory Information, https://www.australia.gov.au/states.
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legislation.108 Other states rely on the NHMRC’s Ethical Guidelines on
Assisted Reproductive Technology in Clinical Practice.109
Similar to the United States, ART regulation in Australia has been
described as “splintered.”110 In Australia, the national government
creates regulatory schemes surrounding issues like embryo research,
the creation of embryos (for research and reproduction), and the
accreditation of reproductive clinics, while individual states and
territories are “responsible for parentage and ART regulation.”111 The
Australian Health Ethics Committee also publishes guidelines, which
are being reviewed “specifically for mitochondrial donation.”112 Also,
similar to the United States, doctors also engage in self‐regulation
through the participation in and adherence to guidelines promulgated
by various societies.113
Until this year, mitochondrial transfer was illegal under
Australian law.114 Before Maeve’s Law, it would have violated the
Prohibition of Human Cloning for Reproduction Act (PHCR) to
108

Karinne Ludlow, The Policy and Regulatory Context of U.S., U.K., and Australian Responses to
Mitochondrial Donation Governance, 58 JURIMETRICS J. 247, 253 n.42 (2018) (“The states with
legislation are New South Wales, South Australia, Victoria and Western Australia.”). See
Assisted Reproductive Technology Act 2007 (N.S.W); Assisted Reproductive Treatment Act
1988 (S.Austl.); Assisted Reproductive Treatment Act 2008 (Vict.); Human Reproductive
Technology Act 1991 (W. Austl.).

109

Ludlow, supra note 46, at 10–11.

110

Id. at 4.

111

Id. at 11.

112

Maeve’s Law Provisions, supra note 50, at 21 (citing NHMRC Submission discussing “Ethical
guidelines on the use of assisted reproductive technology in clinical practice and research.”).

113

For more on self‐regulation of ART in the U.S., see Jennifer L. Rosato, The Children of Art
(Assisted Reproductive Technology): Should the Law Protect Them from Harm?, 2004 UTAH L. REV.
57, 65 (2004) (“The American Society for Reproductive Medicine (‘ASRM’) is the primary
professional organization that oversees the field of reproductive medicine, and the Society of
Assisted Reproductive Technology (‘SART’), an affiliated organization, specifically covers
IVF programs, in addition to other types of ART programs.” (citations omitted)). For more on
self‐regulation of ART in Australia, see Ludlow, supra note 109, at 253; NAT’L HEALTH & MED.
RSCH. COUNCIL, MITOCHONDRIAL DONATION ISSUES PAPER: ETHICAL AND SOCIAL ISSUES FOR
COMMUNITY
CONSULTATION
(2019),
https://www.nhmrc.gov.au/sites/default/files/documents/attachments/Mitchondrial‐
Donation‐Issues‐Paper.pdf.

114

The Honorable Greg Hunt MP, Minister for Health and Aged Care, , Explanatory Memorandum
to
Accompany
Maeve’s
Bill,
https://parlinfo.aph.gov.au/parlInfo/download/legislation/ems/r6697_ems_34f56965‐6288‐
4da6‐9a02‐096f5b58d3c1/upload_pdf/JC001678.pdf;fileType=application%2Fpdf.
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develop an embryo containing the genetic material of more than 2
individuals.115 Similarly, it would have violated the PHCR to make any
heritable changes to “the genome of a human embryo for reproductive
purposes,” meaning that the Australian government interpreted
“heritability” to include mitochondrial transfer, similar to the FDA’s
current interpretation of the word.116 Like in the United States,
mitochondrial transfer in Australia faces opposition from many
directions, including Catholic religious figures.117 Others oppose the
use of mitochondrial transfer based on “slippery slope” concerns that
using mitochondrial donation could later lead to human reproductive
cloning.118
In 2018, the Australian Senate examined scientific, legal, and
ethical issue related to mitochondrial transfer.119 After this
examination, the Senate issued a report and recommended further
consultation with multiple stakeholders and regulatory actors before
the process was used in Australian clinical practice.120 In June 2021, a
committee of members of Parliament released a report that
recommended a public consultation in relation to proposed legislative
changes within Australia to permit mitochondrial transfer.121 The
committee charged with writing the Senate’s report concluded by
noting that “[t]he committee makes no recommendations as this is a
conscience matter.”122
115

Maeve’s Law Provisions, supra note 50, at 11; NAT’L HEALTH & MED. RSCH. COUNCIL,supra note
113. .

116

Maeve’s Law Provisions, supra note 50, at 11.

117

See, e.g., Marilyn Rodrigues, Bishops Warn of Risks of Mitochondrial Donation Tech, CATHOLIC
WEEKLY (Mar. 21, 2021), https://www.catholicweekly.com.au/bishops‐warn‐of‐risks‐of‐
mitochondrial‐donation‐tech.

118

Maeve’s Law Provisions, supra note 50, at 27.

119

Explanatory Memorandum, Mitochondrial Donation Law Reform (Maeve’s Law) Bill 2021
(Cth)
2
(Austl.),
https://parlinfo.aph.gov.au/parlInfo/download/legislation/ems/r6697_ems_34f56965‐6288‐
4da6‐9a02‐096f5b58d3c1/upload_pdf/JC001678.pdf;fileType=application%2Fpdf.
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Id.
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Nogrady, supra note 7; Parliament of Australia, Report: Science of Mitochondrial Donation and
Related
Matters,
List
of
Recommendations,
https://www.aph.gov.au/Parliamentary_Business/Committees/Senate/Community_Affairs/
MitochondrialDonation/Report/b01.
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Maeve’s Law Provisions, supra note 50, at 43; see Chapter 4: Ethics of Mitochondrial Donation,
AUSTL.
COMM.
CMTY.
AFFS.,
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Australia’s Minister for Health and Aged Care, the Honorable
Greg Hunt MP, introduced Maeve’s Bill, his proposal to legalize
mitochondrial transfer.123 Under that proposal, the regulatory
framework would focus on the issuance of licenses for mitochondrial
transfer being administered by the National Health and Medical
Research Council (NHMRC).124 Currently, the NMHRC maintains that
some research could be conducted under current licensing; however,
no human clinical use of mitochondrial transfer is permissible at this
time.125 Licenses would be available in 5 stages, which is arguably
similar to the FDA’s multi‐stage drug approval process.126 The stages
of the Australian licenses include research and training licenses, which
one might expect would not be required in the U.S. depending on the
type of research.127 In Australia, only 2 mitochondrial transfer
techniques would be permitted: maternal spindle transfer and
pronuclear transfer.128 On December 1, 2021, the Australian House of
Representatives passed Maeve’s bill by a vote of 92 to 29.129 The bill
passed in the Australian Senate in March 2022 .130

D. “Comparator” Differences
Before addressing the lessons that the United States might learn
from Australia and the U.K., I acknowledge that some would dismiss
a comparative approach or emphasize the differences amongst the
three countries. There are, admittedly, some differences. One

https://www.aph.gov.au/Parliamentary_Business/Committees/Senate/Community_Affairs/
MitochondrialDonation/Report/c04 (last visited Sept. 22, 2021).
123

See generally Explanatory Memorandum, supra note 119.

124

Maeve’s Law Provisions, supra note 50, at 3.

125

NAT’L HEALTH & MED. RSCH. COUNCIL, supra note 113.

126

Maeve’s Law Provisions, supra note 50, at 5 (“a pre‐clinical research and training licence; a
clinical trial research and training licence; a clinical trial licence; a clinical practice research
and training licence (only available under stage 2); and a clinical practice licence (only
available under stage 2)”) (citing the Explanatory Memorandum to the Bill); see also Step 3:
Clinical
Research,
U.S.
FOOD
&
DRUG
ADMIN.
(Jan.
4,
2018),
https://www.fda.gov/patients/drug‐development‐process/step‐3‐clinical‐research.
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See Maeve’s Law Provisions, supra note 50, at 22.
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Mitochondrial Donation Law Reform (Maeve’s Law) Bill 2021, supra note 15, at 35.
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Martin, supra note 15.
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Mitochondrial Donation Law Reform (Maeve’s Law) Bill 2021, supra note 15.
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noteworthy difference involves the amount of religious influence on
regulation varies across the countries. Within the U.K., there are state‐
sponsored churches, yet many observers view the United States as
more religious than the United Kingdom or Australia.131 In its
Supplementary Submission related to Maeve’s bill, the Mito
Foundation stated that the United States was not an “appropriate
comparator” when assessing whether mitochondrial transfer should
go forward in Australia because “there are a number of religious and
other elements at work in the United States that impact access to
women’s health, including IVF, birth control, and abortion.”132 While
this assessment of the comparative differences between the U.S. and
Australia is certainly accurate, the differences between the U.K. and
Australia on the one hand and the United States on the other hand, do
not hinder the Article’s overall aims, which are to foster discourse and
to ascertain how one might structure a “piecemeal” or “segmented”
approach to the legalization of mitochondrial transfer in the U.S.
Australia has legislation and substantive regulations related to
ART, whereas the United States is notable for the lack of clearly
applicable federal substantive law related to forms of ART involving
genetic innovation.133 Individuals and governmental actors in the U.S.,
U.K., and Australia have different views on whether mitochondrial
transfer is genetic modification and the significance of that genetic
modification.134 For example, the U.K. Department of Health
concluded that mitochondrial transfer was not genetic modification

131

See generally U.S. DEP’T STATE, OFF. INT’L RELIGIOUS FREEDOM, 2020 REPORT ON INTERNATIONAL
RELIGIOUS
FREEDOM:
UNITED
KINGDOM
(2021),
https://www.state.gov/wp‐
content/uploads/2021/05/240282‐UNITED‐KINGDOM‐2020‐INTERNATIONAL‐
RELIGIOUS‐FREEDOM‐REPORT.pdf; Dalia Fahmy, Americans Are Far More Religious Than
Adults
in
Other
Wealthy
Nations,
PEW
RSCH.
(July
31,
2018),
https://www.pewresearch.org/fact‐tank/2018/07/31/americans‐are‐far‐more‐religious‐than‐
adults‐in‐other‐wealthy‐nations/.

132

MITO FOUND., Mitochondrial Donation Law Reform (Maeve’s Law) Bill 2021 Submission 16 –
Supplementary Submission, at 6 (Aug. 10, 2021) (Austl.).
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Maeve’s Law Provisions, supra note 50, at 1 (Maeve’s law would modify the following
legislation: “the Prohibition of Human Cloning for Reproduction Act 2002 (PHCR Act)[;] the
Research Involving Human Embryos Act 2002 (RIHE Act) [;] the Research Involving Human
Embryos Regulations 2017 (RIHE Regulations) [;] the Therapeutic Goods (Excluded Goods)
Determination 2018 (Excluded Goods Determination), [;] and the Freedom of Information Act
1982 (FOI Act)”).

134

See discussion supra, Part I., Section B.
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whereas currently, the FDA’s interpretation of the Congressional
budget rider prohibiting “heritable genetic modification” includes
mitochondrial transfer.135
The three countries analyzed in this Article also have varying
views on entitlements to donor information and the significance of
genetic donors. In the U.K., mitochondria are generally not seen as
significant to identity which, at least in bioethics discourse, tends to
focus on nuclear DNA.136 In the U.K., children conceived as a result of
mitochondrial donation would not be entitled to information related
to their mitochondrial donor.137 In the U.S., children created using IVF
are not entitled to information related to their donor, whereas Maeve’s
law will permit children born as a result of mitochondrial transfer to
“apply for identifying information about their donor when they turn
18.”138 Similar to the treatment of parentage in the U.S., mitochondrial
egg donors in Australia would not be legal parents of the children
conceived using mitochondrial transfer, an issue that is resolved by
state law in the U.S. as opposed to federal law.139 Australians have
taken a markedly different direction on the issue of sex selection than
many Americans. For example, the National Academies of Sciences
recommended that only male embryos be implanted in order to avoid
issues related to the “heritability” of mitochondrial changes, whereas
the Australian legislation leaves the issue of sex selection to the
parents.140

135

See Ludlow, supra note 108, at 256 (“According to the U.K. Dep’t of Health Report, genetic
modification requires “germline modification of nuclear DNA . . . that can be passed on to
future generations.”) (citing Public consultations: Health Sci. & Bioethics Div., Dep’t of
Health, Mitochondrial Donation: Draft Regulations to Permit the Use of New Treatment
Techniques to Prevent the Transmission of a Serious Mitochondrial Disease from Mother to
Child (2014)); U.S. FOOD & DRUG ADMIN., Advisory on Legal Restrictions on the Use of
Mitochondrial Replacement Techniques to Introduce Donor Mitochondria into Reproductive Cells
Intended for Transfer into a Human Recipient (Mar. 16, 2018), https://www.fda.gov/vaccines‐
blood‐biologics/cellular‐gene‐therapy‐products/advisory‐legal‐restrictions‐use‐
mitochondrial‐replacement‐techniques‐introduce‐donor‐mitochondria; Letter from Mary A.
Malarkey, supra note 77, at 1.

136

See discussion supra Part I.
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See Maeve’s Law Provisions, supra note 50, at 7; Mitochondrial Donation, supra note 16.
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See id.
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See id.; NAT’L ACAD. SCIS., ENG’G & MED., SUPRA NOTE 2810 (noting the acceptability of sex
selection for medical reasons).

MYRISHA S. LEWIS

347

In Australia, parents who would use mitochondrial transfer
would also be subject to counselling requirements, an approach that
seems unlikely in the United States, although issues related to follow‐
up would likely arise.141 For example, across the world, follow‐up
studies are often difficult in ART as happy parents no longer want to
continue visiting fertility providers and subjecting children to the
requirements of follow‐up studies such as tissue samples.142 Whether
parents should be able to decide whether to include their children in
future follow‐up studies is an ethical issues that arises in discussions
of mitochondrial transfer.143 The U.K.’s mitochondrial donation
treatments are accompanied by expected follow‐up appointments for
children conceived using mitochondrial transfer at eighteen months
and five years old.144 Additionally, while much attention is paid to the
issue of physical follow‐up, others in Australia have testified to the
need for a registry that focuses not only on scientific issues but
psychosocial implications.145 As has arisen in debates regarding ART
and all forms of ART involving genetic modification or substitution,
observers note that the risks of the techniques to the child and
subsequent generations are unknown, however that is the case with
many FDA‐approved products.146 Follow‐up studies have been
recommended a part of recent FDA gene therapy approvals.147 In light
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See Maeve’s Law Provisions, supra note 50, at 19.
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Lyndsey Craven et al., Scientific and Ethical Issues in Mitochondrial Donation, 24 THE NEW
BIOETHICS J. 57, 67–68 (2018); See, e.g., Transcript, Center for Biologics Evaluation and Research,
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9,
2002,
8:00
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Parents, or Offspring?, 25 THE NEW BIOETHICS J. 3 (2018) (arguing for parental determinations
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for the long‐term follow‐up monitoring of gene therapy recipients for delayed adverse events
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of the concern for future generations (a concern that generally does not
limit natural reproduction), it is possible that, like in Australia, where
some have suggested writing follow‐up studies into the legislation, the
U.S. may, if mitochondrial transfer is approved through FDA
regulatory pathways, consider including follow‐up studies in future
approvals.148
Even though the U.K. takes a markedly more restrictive approach
to access to donor information in the context of ART, lack of donor
information thus far has not precluded IVF’s legality in the U.S. and is
likely an insignificant factor in regulation.149 In other words, while
some object to mitochondrial transfer as “three‐parent IVF,” those
individuals tend to give little emphasis to the identity or information
about that “third parent”.150
The U.S. is known for its “unregulated” or “minimally regulated”
approach to assisted reproductive technology, where only one federal
statute, the Federal Clinic Success Rate Act, directly addresses assisted
reproductive technology.151 The U.S. has used budget riders and
generally unreviewable agency action to regulate mitochondrial
(FDA Guidance for Industry: Gene Therapy Clinical Trials—Observing Subjects for Delayed
Adverse Events, 2006a).”); Summary Minutes of the Oncologic Drugs Advisory Committee, U.S.
FOOD & DRUG ADMIN. CTR. FOR DRUG EVALUATION & RSCH. (July 12, 2017), at 6 (transcript
available at https://fda.report/media/107129/Minutes‐for‐the‐July‐12—2017‐Meeting‐of‐the‐
Oncologic‐Drugs‐Advisory‐Committee‐%28ODAC%29.pdf) (“A committee member stated
concern over unknown late toxicities, but that long term survival outweighs that potential
risk.”).
148

See Maeve’s Law Provisions, supra note 50, at 15; see also Karinne Ludlow et al., Mitochondrial
Donation Law Reform (Maeve’s Law) Bill 2021 Submission 48 ( (noting that the phrasing of the
monitoring requirements in the legislation “raises the question of whether children born
under a clinical practice license . . . are considered patients . . . and that patient monitoring
obligations apply, or whether the intention is that once approved for clinical use, MDT will
be treated as any other ART IVF procedure.”).

149

Guidance regarding gamete and embryo donation, AM. SOC’Y REPROD. MED. (Jan. 20, 2021),
https://www.asrm.org/globalassets/asrm/asrm‐content/news‐and‐publications/practice‐
guidelines/for‐non‐members/recs_for_gamete_and_embryo_donation.pdf; Donors, HFEA
(Sept. 18, 2022), https://www.hfea.gov.uk/donation/donors/.
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As online genetic databases continue to increase in use, anonymous donation may be
rendered less anonymous over time. See generally Seema Mohapatra, The Myth of
“Anonymous” Gamete Donation in the Age of Direct‐to‐Consumer Genetic Testing, in CONSUMER
GENETIC TECH.: ETHICAL & LEGAL CONSIDERATIONS 94–104 (I. Glenn Cohen, Nita Farahany,
Henry Greely, & Carmel Shachar eds., 2021).
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See 42 U.S.C. §§ 263a‐1; Lewis, How Subterranean Regulation Hinders Innovation in Assisted
Reproductive Technology, supra note 17, at 1241 n. 1 (providing a literature review).
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transfer.152 Those choices have led to a regulatory standstill. Yet, by
targeting forms of ART involving genetic modification for the FDA’s
investigational new drug requirement, the agency has arguably laid
the groundwork for a more HFEA‐like regime, like in the U.K. where
a government agency is responsible for determining matters such as
which ART techniques are available and the conditions under which
individuals can access those techniques. Ultimately, differing
constitutional structures, varied national‐ and state‐level decisions on
matters like donor information, and differing allocations of legal issues
to federal and state jurisdiction do not preclude a comparative analysis
or the use of solutions based on the Australian or U.K. experiences
with mitochondrial transfer. The next Part of the Article identifies
useful aspects of the U.K. and Australian approaches to the
legalization of mitochondrial transfer in order to make structural
suggestions for the U.S. going forward.

III. Segmented Innovation for the United States: Applying the
Experiences of the U.K. and Australia to the American
Regulation of Mitochondrial Transfer
Mitochondrial transfer is now legal in the U.K. and Maeve’s Law
has paved the way for its potential clinical use in Australia. In a
previous article, I analyzed the United Kingdom’s process of legalizing
mitochondrial transfer in light of the American “democratic deficit” in
the federal regulation of assisted reproductive technology.153
Regardless of the fate of Maeve’s Bill, the processes that Australia and
the U.K. have used could provide useful insights to be implemented
in the United States. In particular, key lessons include educating the
public about the underlying science of these techniques, to minimize
sensationalism, and multiple forms of public consultation that extend
beyond gathering comments from the public like with notice‐and‐
comment rulemaking.

152

See supra notes 72‐78 and accompanying text.

153

See Myrisha S. Lewis, The American Democratic Deficit in Assisted Reproductive Technology
Innovation, 45 AM. J.L. & MED. 130, 145–48, 164–68 (2019).
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A. Public Consultation Beyond Notice and Comment
Rulemaking
Public deliberation or engagement is a broad term that
encompasses a number of goals including transparency, education,
and “bring[ing] an informed democratic process to decisions.”154 Many
methods of deliberative democracy exist, including “public
communication,” “public consultation,” “public involvement,”
“public collaboration” like consensus conferences, and “public
empowerment.”155 Public deliberation or engagement would be useful
in the United States as it could serve to (1) educate the public, (2)
connect groups that usually do not interface with each other, including
federal agency employees and the general public, (3) satisfy scientists’
and bioethicists’ calls for public consultation in the area of
reproductive genetic innovation, and (4) broaden the perspectives
available to legislators and agency officials.156
Public involvement in decision‐making comprises a range of
actions from passive (such as soliciting public input) to more active
(like voting). Public opinion polls are one method of public
engagement; however, they tend to be carried out by non‐
governmental entities, like the Pew Research Center or the now‐
defunct Genetics and Public Policy Center at Johns Hopkins University
instead of administrative agencies.157 Public communication can
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See, e.g., NAT’L ACAD. SCIS., ENG’G, & MED., REFLECTING SUNLIGHT: RECOMMENDATIONS FOR
SOLAR GEOENGINEERING RSCH. & RSCH. GOVERNANCE 154 (2021); Albert C. Lin, Mismatched
Regulation: Genetically Modified Mosquitoes and the Coordinated Framework for Biotechnology, 51
U.C. DAVIS L. REV. 205, 230–31 (2017); see also KRISTEN L. CARMAN ET AL., REPORT FOR AGENCY
FOR HEALTHCARE RESEARCH AND QUALITY, PUBLIC DELIBERATION TO ELICIT INPUT ON HEALTH
TOPICS: FINDINGS FROM A LITERATURE REVIEW ii at ES‐5, 18‐20 (“Public deliberation—a method
of public consultation in which members of the public come together to engage in informed
dialogue about difficult or complex social issues—can be implemented via several different
designs and methodologies.”).
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Dietram A. Scheufele et al., What We Know About Effective Public Engagement on CRISPR and
Beyond, PNAS (2021), at 4–5, https://www.pnas.org/doi/epdf/10.1073/pnas.2004835117.
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See also CARMAN ET AL., supra note 154, at ES‐4 (“Deliberation is governed by the principle of
mutual sharing of perspectives and respect for differing points of view”) (citations omitted).
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See Monique Harris, Americans Divided Over Genetic Manipulation, THE GAZETTE ONLINE (Dec.
16,
2002),
https://pages.jh.edu/gazette/2002/16dec02/16divide.html
[https://www.pewtrusts.org/en/projects/archived‐projects/genetics‐and‐public‐policy‐
center]; Susannah Baruch, Preimplantation Genetic Diagnosis and Parental Preferences: Beyond
Deadly Disease, 8 HOUS. J. HEALTH L. & POL’Y 245, 252 (2008); Cary Funk et al., U.S. Public Wary
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include agency outreach and the providing of information; it is often a
part of public consultation.158 Public involvement, which can be part of
a public consultation, can also include deliberative opinion polls that
assess the views of members of the public before and after expert
deliberations.159 Public consultation, like that which has occurred in
the United Kingdom and Australia involves soliciting public feedback
and considering as part of the regulatory process.160 Public
empowerment, such as the empowerment that occurs in the context of
ballot initiatives in the United States, involves direct decision‐making
by the public, but is unlikely in the case of mitochondrial transfer at
the federal level although it could be possible in an individual state in
the future.161
In countries that have legalized mitochondrial transfer, public
consultation has been a part of the societal and legal conversations.162
Public consultations, which involve far more outreach than the United
States’ notice and comment processes, agency‐led public meetings,
and lack of administrative agency discussion altogether, have been
used in both the United Kingdom and Australia.163 Part of the U.K.
and Australian experiences with mitochondrial transfer have included
public outreach and a societal discourse. In the United Kingdom, the
five‐strand public consultation that preceded the legalization of
mitochondrial transfer involved “…deliberative public workshops,
…[a] public representative survey,…[an] open consultation

of Biomedical Technologies to ‘Enhance’ Human Abilities, PEW RSCH. CTR. (Jul. 26, 2016),
https://www.pewresearch.org/science/2016/07/26/u‐s‐public‐wary‐of‐biomedical‐
technologies‐to‐enhance‐human‐abilities/.
158

Scheufele et al., supra note 155, at 4.

159

Id.; supra Part III.A.

160

Scheufele et al., supra note 155, at 4; supra Part III.A.

161

Scheufele et al., supra note 155, at 5; See e.g., Julian N. Eule, Judicial Review of Direct Democracy,
99 YALE L.J. 1503, 1509 (1990) (discussing state ballot initiatives and other methods of direct
democracy).

162

See discussion supra Part II.
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See, e.g., 5 U.S.C. § 553; Catherine M. Sharkey, Federalism Accountability: “Agency‐Forcing”
Measures, 58 DUKE L. J. 2125, 2163 (2009) (“Notice‐and‐comment rulemaking is the means by
which federal agencies solicit and incorporate the views of all “interested persons” before
issuing final rules.”); Nicholas Bagley, The Procedure Fetish, 118 MICH. L. REV. 345 (2019); See
supra notes 40‐41 and accompanying text (providing and analyzing a 2014 FDA employee
statement at an Advisory Committee meeting).
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questionnaire,…open consultation meetings…and patient focus
groups.”164
Citizens’ juries or citizens’ panels are another method of
addressing a “democratic deficit” in regulation as they aim to increase
public participation in government.165 At the same time, critics of
citizens’ juries note that “[w]hile it is agreed that citizens should share
in decision‐making, there is no feeling that they should be involved in
the process of governing more directly.”166 Citizens’ juries have been
used to obtain public views on a number of matters related to health
care in the United Kingdom and Australia.167 Citizens’ juries are also
used in other such as Canada, European Union Member States, the
United States, and India.168 Notably, Professor Ainsley Newson and
colleagues convened a citizens’ jury on mitochondrial transfer in
Australia and published the results.169
In Australia, various governmental bodies acted to inform the
public and solicit their views. In 2018, the Australian Senate
Community Affairs Committee published, Science of mitochondrial

164

SARAH BARBER & PETER BORDER, MITOCHONDRIAL DONATION 13 (2015),
https://researchbriefings.files.parliament.uk/documents/SN06833/SN06833.pdf;
James
Gallagher, UK Government Backs Three‐Parent IVF, BBC NEWS (June 27, 2013),
www.bbc.co.uk/news/health‐23079276 [https://perma.cc/5KDD‐LP3F]; HUM.FERTILISATION &
EMBRYOLOGY AUTH., ANNUAL REPORT & ACCOUNTS, CHAIR AND CHIEF EXECUTIVE’S FOREWORD
4–5
(2012‐2013),
https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_d
ata/file/246699/0323.pdf.

165

See, e.g., Lewis, supra note 153; Bagley, supra note 163, at 372 (“Agencies are also said to labor
under an acute democratic deficit: they lack the populist pedigree of either the legislature or
the president, yet they wield immense government power.”); Susan Pickard, Citizenship and
Consumerism in Health Care: A Critique of Citizens’ Juries, 32 SOC. POL’Y & ADMIN. 226, 226
(1998); Rachel Krinks et al., Do Consumer Voices in Health‐Care Citizens’ Juries Matter?, 19
HEALTH EXPECTATIONS 1015, 1016 (2015).

166

Pickard, supra note 165, at 227.
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Gerry King et al., Exploring Public Perspectives on E‐Health: Findings from Two Citizen Juries, 14
HEALTH EXPECTATIONS 351, 351–59 (2010); Jackie Street et al., The Use of Citizens’ Juries in
Health Policy Decision‐Making: A Systematic Review, 109 SOC. SCI. & MED. 1, 1–6 (2014).
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Street et al., supra note 167, at 1‐4; Devidas Menon & Tania Stafinski, Engaging the Public in
Priority‐Setting for Health Technology Assessment: Findings from a Citizens’ Jury, 11 HEALTH
EXPECTATIONS 282, 285 (2008).
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Ainsley Newson et al., Public Attitudes Towards Novel Reproductive Technologies: a Citizens’ Jury
on Mitochondrial Donation, 34 HUM. REPROD. 751 (2019).
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donation and related matters.170 In 2019, the Committee released
information related to mitochondrial donation and opened a
submission portal so that members of the public could submit their
views on mitochondrial transfer.171 In addition to the Citizens’ Jury
convened by Professor Newson and colleagues in Australia, the
NHMRC convened its own citizens’ panel which met over two
weekends: once in October 2019 and once in November 2019.172 As part
of the citizens’ panel, citizens attended presentations by scientific,
medical, legal, and ethical experts. 173 The Citizens’ Panel published a
statement after its convention.174 The NHMRC also conducted multiple
webinars, posted videos, and used roundtables to solicit the views of
experts in the field.175 In 2020, the NHMRC published the report of the
Mitochondrial Donation Expert Working Committee.176 Later that
year, the NHMRC released a report that summarized the agency’s
findings.177
In 2021, as part of the public outreach portion of the leadup to
Maeve’s bill, the Australian government received 60 submissions in a
public consultation.178 Some submissions were less than 2 pages long
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See generally CMTY. AFFS. REFERENCES COMM., SCIENCE OF MITOCHONDRIAL DONATION AND
RELATED
MATTERS
(2018),
https://www.aph.gov.au/Parliamentary_Business/Committees/Senate/Community_Affairs/
MitochondrialDonation/Report.
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Mitochondrial
Donation,
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&
MED.
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Consultation:
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Statement
3,
https://www.nhmrc.gov.au/sites/default/files/documents/attachments/Citizens%27‐panel‐
position‐statement.pdf [hereinafter NAT’L HEALTH & MED. RSCH. COUNS., Mitochondrial
Donation Community Consultation].
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Id. at 2‐3.
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NAT’L HEALTH & MED. RSCH. COUNS., Mitochondrial Donation Community Consultation, supra
note 172.

176

Mitochondrial Donation, supra note 171.
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NAT’L HEALTH & MED. RSCH. COUNS., REPORT ON NHMRC’S PUBLIC CONSULTATION ON THE
SOCIAL AND ETHICAL ISSUES RAISED BY MITOCHONDRIAL DONATION (CONSULTATION REPORT),
file:///C:/Users/bebea/Downloads/Consultation‐report.pdf.

178

Mitochondrial Donation, supra note 16 (“A public consultation process on the proposed
approach to introducing mitochondrial donation in Australia, ran from 5 February 2021 until
15 March 2021.”); NAT’L HEALTH & MED. RSCH. COUNS., Mitochondrial Donation Community
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while others were much longer.179 Submissions by members of the
public also included scientific background including benefits and risks
or side effects of the techniques, recommendations for or against the
techniques, and questions about aspects and implications of the bill.180
This effort went beyond the U.S. approach to mitochondrial transfer,
which has involved no solicitation of public comment and no
discussion through public hearings either. Later, the Article will draw
on this combination of public input as combined with legislative
hearings that include legislative consideration and expert testimony,
as part of its recommendations for the United States.
The Australian Senate’s Community Affairs Legislation
Committee held “Senate Inquiry Hearings” on August 6, 2021, which
involved the testimony of scientists including the President of the
ISSCR, George Daley, who is also the Dean of Harvard Medical
School.181 Commenters had access to public submissions before the
Senate Inquiry Hearings and several incorporated those submissions
into their testimony.182 The ISSCR supports Maeve’s bill “because it
would establish a rigorous, incremental approach to enable MRT to
prevent the transmission of mitochondrial diseases that is consistent
with the process described in the ISSCR guidelines….[and] provides a
process for evaluating the safety and efficacy of MRT before making it
available more broadly in clinical practice.”183 The ISSCR was also
Consultation, supra note 172.
179

See, e.g., Mitochondrial Donation Law Reform (Maeve’s Law) Bill 2021, Submission 6 (Tiffany
Boughtwood, Managing Director, Australian Genomics).

180

See, e.g., Mitochondrial Donation Law Reform (Maeve’s Law) Bill 2021, Submission 53 (Dr.
Gregory K. Pike, Director, Adelaide Centre for Bioethics and Culture, Submission to Senate
Community Affairs Committee re Mitochondrial Donation Law Reform Bill, Aug. 2, 2021);
Mitochondrial Donation Law Reform (Maeve’s Law) Bill 2021, Submission 55 (Professor
Julian Savulescu, Murdoch Children’s Research Institute, July 16, 2021); Mitochondrial
Donation Law Reform (Maeve’s Law) Bill 2021, Submission 4 (Rare Voices Australia
Submission, July 2021); Mitochondrial Donation Law Reform (Maeve’s Law) Bill 2021,
Submission 5 (Monash IVF Group, Jul. 14, 2021). For sources opposed to Maeve’s Bill, see, for
example, Mitochondrial Donation Law Reform (Maeve’s Law) Bill 2021, Submission 7
(Professor Megan Best, University of Notre Dame Australia, Jul. 7, 2021).

181
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Bill
2021,
Aug.
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2021,
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MitochondrialLawReform/Public_Hearings; Public Hearing Transcript, supra note 10, at 19–27..
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cited in the National Academies Mitochondrial Replacement Techniques
report as having established guidelines for the ethical use of human
embryos in research.184 Thus, in addition to examining the successful
experiences of other countries, when considering the future of
mitochondrial transfer in the U.S., governmental actors should
consider that groups in the U.S. and abroad have already contributed
to an expert consultation process.
In the United States, agencies have used some of the techniques of
public involvement, but more can be done. The Department of Health
and Human Services used public outreach methods such as “listening
sessions” in the leadup toward establishing “essential health benefits”
even though it was not required by the Administrative Procedure
Act.185 Thus, although the FDA, an operating division of the U.S.
Department of Health and Human Services is not known for taking
such a public‐facing approach on issues of moral, political, or social
controversy, it could certainly do so.186 Increasing public interactions
outside of the notice and comment process might have an “equalizing”
impact on access, as many FDA employees speak at industry events
(often with financial requirements for attendance) or interface with
patients through FDA‐established patient groups, but these
interactions do not include the general public.187 Beyond that, there are
many options for public engagement, as identified by a report issued
by another operating division of the U. S. Department of Health and
Human Services, the Agency for Healthcare Research and Quality.188
Even if the FDA did not lead efforts at public engagement and those
efforts were left to other sponsors like individual state actors or private

Little, President, ISSCR, July 16, 2021), available at https://www.isscr.org/isscr‐news/the‐isscr‐
comments‐on‐the‐australian‐mitochondrial‐donation‐bill.
184

NAT’L ACAD. SCIS., ENG’G & MED., supra note 28, at 12.

185

Nicholas Bagley & Helen Levy, Essential Health Benefits and the Affordable Care Act: Law and
Process, 39 J. HEALTH POL. POL’Y & L. 441, 443–49 (2014).

186

See About HHS, U.S. DEP’T HEALTH & HUM. SERVS., https://www.hhs.gov/about/agencies/hhs‐
agencies‐and‐offices/index.html.
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See, e.g., Molecular Med. Tri‐Conference, Interview of Peter Marks by Christine Lingham,
Mar. 1‐4, 2020, https://www.triconference.com/transcripts/peter‐marks‐transcript; Food and
Drug Law Institute, Fundamentals of Vaccine Regulation: Scientific Ingenuity and Rigorous Review,
Feb. 4, 2021 Virtual Course, https://www.fdli.org/2021/02/fundamentals‐of‐vaccine‐regulation‐
scientific‐ingenuity‐and‐rigorous‐review/.
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CARMAN ET AL., supra note 154; About HHS, supra note 186.
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groups, there would still be some value to obtaining societal
perspectives and fostering societal discourse on techniques involving
reproductive genetic innovation. As legislators and interested parties
continue to consider the legal framework that will accompany
techniques involving genetic changes in the United States, it is worth
framing those techniques in a manner that is accessible to the public
and that minimizes the sensational views that accompany
reproductive genetic innovation.
Constructing a public consultation related to mitochondrial
transfer would exceed the space allotted in this Article, but this Article
notes some of the areas that could be considered in that consultation.189
Such a consultation could be conducted at the federal level, by the U.S.
Food and Drug Administration (because it is currently seen as the
regulator of these techniques) or by other agencies within the U.S.
Department of Health and Human Services, such as the National
Institutes of Health, which is arguably more interested in the
educational and bioethical aspects of medical innovations.190
Part of that consideration should likely include the stories of
individuals who have used the techniques. While many who are
seeking to have pharmaceuticals approved by the FDA have been
vocal (and successful) at having those pharmaceuticals approved,
those interested in using reproductive genetic innovation have been
less successful and visible. Part of an American public consultation,
whether orchestrated by Congress, the FDA, or another administrative
agency, should include stories from individuals who have suffered

189

In a companion article, I have emphasized the potential usefulness of a discourse related to
all techniques involving reproductive genetic innovation, which includes cytoplasmic
transfer, mitochondrial transfer, and germline gene editing. See Myrisha S. Lewis, Normalizing
Reproductive Genetic Innovation (on file with author).

190

In the past, the NIH administered a Consensus Development Review program which fostered
communications among experts on various medical topics. See THOMAS STARZL, PUZZLE
PEOPLE: MEMOIRS OF A TRANSPLANT SURGEON 162, 252‐54, 269 (U. of Pitt. Press 1992); NIH
Consensus Development Program, Retirement of the National Institutes of Health Consensus
Development Program, NAT’L INSTS. HEALTH, https://consensus.nih.gov. The NIH is not
necessarily neutral as it has expressed an opposition to applications involving germline
genetic modification for decades. See Carrie D. Wolinetz & Francis S. Collins, NIH Supports
Call for Moratorium on Clinical Uses of Germline Gene Editing, 567 NATURE 175 (2019),
https://www.nature.com/articles/d41586‐019‐00814‐6. In terms of bioethical conversations,
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connection with patient care and clinical research at the NIH. See Bioethics Consult Service,
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MYRISHA S. LEWIS

357

from mitochondrial disease and who might also want to avail
themselves of these technologies.191 Furthermore, it might be useful to
have the perspectives of those who have used or been conceived using
cytoplasmic transfer as that is the most similar technique of
reproductive genetic innovation that has been used in the U.S.192
Similarly, stakeholder perspectives, including those of individuals
who have obtained mitochondrial transfer or who wish to do so,
would likely need to be represented. For example, “the lobbying for
universal [newborn] screening [in the U.S.] relied on dramatic
testimonies of parents.”193 Patient perspectives have been included
within FDA Advisory Committees for years. For example, in response
to Executive direction, the FDA added voting patient representatives
to FDA Advisory Committees tasked with addressing cancer‐related
issues.194 While there is a debate within the FDA literature on the
appropriateness of patient perspectives in regulatory decisions (and
the connection between those patient perspectives and drug approval),
the FDA’s Patient Representative Program appoints individual
patients and advocates as “Special Government Employees,” if they
are not already “regular” government employees who are then able to
provide “direct input to agency staff … on their experiences with
various diseases, conditions, and devices while gaining access to

191

See, e.g., Mitochondrial Donation Law Reform (Maeve’s Law) Bill 2021, Submission 16 (Mito
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Shelley Beverley).

192
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mitochondrial transfer).

193
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NEWBORN GENETIC SCREENING 45‐48, 59 (University of Chicago Press, 2012) (discussing the
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confidential information.”195 FDA Patient Representatives also
interface with other groups of experts who are affiliated with the FDA
such as members of Advisory Committees.196 Currently, the FDA
Patient Representative program encompasses a number of
“recruitment areas” including naloxone use, obesity, HIV, and retinitis
pigmentosa.197 This program, however, is not sufficient as a public
consultation because it does not resolve transparency concerns but
rather leads to a different kind of influence on agency decision‐making
that is still outside of public scrutiny.198
There are disadvantages to public consultations. For example, the
lack of a public consultation can permit an issue to remain unregulated
and thus legal, like surrogacy in some states, or in vitro fertilization in
general, which is viewed as unregulated.199 Yet, while there has been
no public consultation related to mitochondrial transfer, the lack of a
public consultation has also corresponded with concise but highly
effective federal regulation. In the U.S., a future public consultation
could include several issues including explanations of the science of
mitochondrial transfer, the role of the FDA in product approval, the
limitations of FDA approval, the impacts of state and federal actions
on parental and reproductive autonomy, disability rights, and other
ethical issues that accompany the use of mitochondrial transfer.200
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B. Re‐interpretation or Removal of the Recurring Federal
Budget Rider
As noted in Part II, in 2015, a rider limiting FDA consideration of
applications involving “heritable genetic modification” was added to
the 2016 budget.201 This budget rider has been renewed each fiscal year
since it was approved in 2015.202 In general, federal budget riders
typically occur without much substantive discussion.203 There are
drawbacks to any approach that involves the federal government:
namely, that any such approach would strengthen a current trend of
increasing federal regulation of the legality of assisted reproductive
technology.204
Although budget riders typically occur without much substantive
discussion, the U.S. could have a much larger conversation
surrounding the currently recurring budget rider.205 Part of that
conversation could include the testimony of individuals who are
affected by mitochondrial disease, as there has been a lack of that
perspective in the limited conversations held in the U.S. This
conversation could motivate the FDA to change its currently
overbroad interpretation of heritable genetic modification as including
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mitochondrial transfer, or influence Congress to write a narrower
budget rider (or none at all).206 At the same time, the budget rider could
have been intended to not only preclude use of the technique in the
United States, but also to discourage discussion of the technique at the
administrative agency level all together.

C. Substantive Congressional Hearings
Moreover, while there have been conversations and testimony at
the level of Congressional subcommittees, perhaps the U.S. should
also consider substantive legislation on mitochondrial transfer. At the
very least, Congress should convene hearings related to the technique
in order to foster conversation similar to what occurred with organ
transplantation decades ago, especially if political and social views
will impact regulatory decision‐making.207
Congressional hearings could be useful not only as they related to
the recurring budget rider but also in terms of a broader societal
discourse. Mitochondrial replacement therapy does not appear to be a
priority on any state or federal legislative agenda. Similarly, there
seems not to be a “Maeve” in the United States who has influenced the
writing of proposed legislation, but there could be. Personal stories
and emotional pleas have also resulted in (and accompanied)
legislative and policy changes in various health areas including
newborn screening and research, treatment, funding, and advocacy for
HIV/AIDS, abortion, and breast cancer.208 Moreover, public
consultation could be employed in the U.S. in at least two ways. First,
any reporting related to public workshops could be shared with
206
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legislators, similar to how evidence from the United Kingdom’s public
workshops was synthesized in a report that was made available before
Parliament changed the U.K. law on mitochondrial transfer.209 Second,
educating legislators about mitochondrial transfer, similar to the
education that individual U.K. participants in HFEA‐sponsored
deliberative workshops, could change regulatory perspectives,
including the views of those who may be indifferent to mitochondrial
transfers use in the United States.210
A broader lesson from the Australian approach to the legalization
of mitochondrial transfer is one in which the United States’ inquiry
into the legalization of mitochondrial transfer occurs in an incremental
manner. Australia pursued a “staged” approach to the potential
legalization of mitochondrial transfer.211 A “cautious, staged”
approach was mentioned by the National Academies of Sciences when
they explained the type of trial design that would need to take place in
clinical investigations related to mitochondrial transfer.212
One issue that arises in the context of public consultations is what
the impact of negative perspectives is on regulatory outcomes. One
might ask: does opposition automatically veto mitochondrial transfer
or similar reproductive genetic innovation techniques? In Australia,
even though many opposed mitochondrial donation, the government
continued to go forward.213 Similarly, in the U.K., negative views did
not prohibit the legalization of mitochondrial transfer. One can expect
that there will be negative views related to the legalization of
mitochondrial transfer in the U.S., yet those negative views should not
necessarily serve as a veto on the legalization of the technique. One can
expect that any discourse in the U.S. would likely result in significant
opposition from various groups including religious groups and those
who are opposed to genetic innovation more broadly. Yet, such groups
are opposed to several other techniques that continue to go forward in
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the U.S., such as stem cell research, abortion, in vitro fertilization and
cryopreservation of eggs and embryos. While religious views have
certainly precluded funding and led to substantial restrictions in
access to techniques (including, especially abortion), thus far, they
have not managed to completely ban the underlying techniques in the
way that reproductive genetic innovation has been stymied in the U.S.
Further, an emphasis on education may serve a particularly limited
role in the United States, as illustrated by recent political opposition
and public resistance to public health measures intended to reduce the
spread of the COVID‐19 pandemic although the U.K. has also
experienced that resistance.214 Yet, if education fails to sway
participants toward legalizing mitochondrial transfer, that education
would still be useful in increasing knowledge and also would result in
the maintenance of the status quo related to the legality of
mitochondrial transfer in the U.S. Moreover, to the extent that
religious, ethical, or moral views are prohibiting the use of
reproductive genetic innovation in the U.S., public consultations and
Congressional hearings can identify those views and facilitate a
conversation as to exactly how influential these views should be.

CONCLUSION
A “staged” or incremental approach still does not eliminate or
resolve many of the ethical debates and arguments that accompany
ART and forms of ART involving genetic modification or substitution
like embryo destruction, long‐term effects, sex selection, and
entitlement to donor information.215 It does, however, provide a
structure for discussing those issues in a more transparent and
publicly available manner than they are currently addressed in the
U.S. It is possible that the United States needs more time with
mitochondrial transfer than the United Kingdom and Australia before
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approving it. As that time unfolds, there are many scientific, ethical,
and safety issues to discuss and several blueprints available on how to
conduct those discussions.

